Intellect Neurosciences 10-K/A 25 Oct 13 2013 FY Annual report (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Jun. 30, 2013	Oct. 15, 2013	Dec. 31, 2012
Document Information [Line Items]
Entity Registrant Name	Intellect Neurosciences, Inc.
Entity Central Index Key	1337905
Current Fiscal Year End Date	-24
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ILNS
Entity Common Stock, Shares Outstanding		285,818,121
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	30-Jun-13
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$1,079,900

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2013	Jun. 30, 2012
ASSETS
Cash and cash equivalents	$5,138	$2,307
Pre-paid expenses	0	19,585
Total current assets	5,138	21,892
Security deposits	4,715	4,715
Total Assets	9,853	26,607
LIABILITIES AND CAPITAL DEFICIENCY
Accounts payable and accrued expenses	2,487,410	2,949,764
Accrued interest - convertible promissory notes	482,298	201,997
Derivative instruments	3,833,457	3,388,482
Preferred stock liability	172,874	518,622
Preferred stock dividend payable	5,350,503	3,605,515
Total Current liabilities	12,326,542	10,664,380
Long Term Debt
Convertible promissory notes	1,231,737	442,155
Total Liabilities	13,558,279	11,106,535
Capital deficiency:
Common stock, par value $0.001 per share, 2,000,000,000 shares authorized; 209,015,899 and 100,240,020 issued and outstanding at June 30, 2013, and June 30, 2012, respectively	209,016	100,240
Additional paid in capital	70,134,497	62,956,267
Deficit accumulated during the development stage	-83,891,966	-74,136,456
Total Capital Deficiency	-13,548,426	-11,079,928
Total Liabilities and Capital Deficiency	9,853	26,607
Series B Convertible Preferred Stock [Member]
Capital deficiency:
Convertible Preferred stock	0	0
Series C Convertible Preferred Stock [Member]
Capital deficiency:
Convertible Preferred stock	20	21
Series D Convertible Preferred Stock [Member]
Capital deficiency:
Convertible Preferred stock	5	0
Series E Convertible Preferred Stock [Member]
Capital deficiency:
Convertible Preferred stock	$2	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
			Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized			1,000,000	1,000,000	25,000	25,000	25,000	25,000	25,000	25,000
Preferred stock, shares issued			106,878	106,878	19,790	20,700	5,466	0	2,000	0
Preferred stock, liquidated (in dollars)			$1,870,380	$1,870,380	$19,790,000	$20,700,000	$5,466,000	$0	$2,000,000	$0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	209,015,899	100,240,020
Common stock, shares outstanding	209,015,899	100,240,020

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended				98 Months Ended
	Jun. 30, 2013		Jun. 30, 2012		Jun. 30, 2013
Revenues:
License fees	$0		$6,500,000		$10,516,667
Total revenue	0		6,500,000		10,516,667
Costs and Expenses:
Research and development	222,300		996,225		14,655,089
General and administrative	4,125,386		5,219,993		45,355,185
Total cost and expenses	4,347,686		6,216,218		60,010,274
Income (loss) from operations	-4,347,686		283,782		-49,493,607
Other income/(expenses):
Interest expense	-6,681,908		-5,581,112		-69,934,864
Interest income					18,525
Changes in value of derivative instruments and preferred stock liability	1,974,084		7,194,320		44,533,393
Gain (Loss) on extinguishment of debt	0		0		-627,809
Other	0		0		-6,587,604
Write off of investment	0		0		-150,000
Total other income/(expense):	-4,707,824		1,613,208		-32,748,359
Net income/(loss)	-9,055,510		1,896,990		-82,241,966
Deemed preferred stock dividend	700,000		0		1,650,000
Net income (loss) allocable to common shareholders	($9,755,510)		$1,896,990		($83,891,966)
Basic income per share (in dollars per share)	($0.07)		$0.02
Diluted income per share (in dollars per share)	($0.07)		$0
Weighted average number of shares outstanding:
Basic (in shares)	136,468,981		81,002,258
Diluted (in shares)	136,468,981	[1]	647,670,189	[1]
[1]	For the year ended June 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Capital Deficiency [Equity] (USD $)	Total	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]
Balance at Jun. 30, 2004		$0	$0	$0	$0	$0	$0
Balance (in shares) at Jun. 30, 2004		0	0	0	0
Issuance of common stock (April 2005) ($.001 per share)	12,078				242	11,836
Issuance of common stock (April 2005) ($.001 per share) (in shares)					241,565
Issuance of common stock (May 2005) ($.001 per share)	9,175				184	8,991
Issuance of common stock (May 2005) ($.001 per share) (in shares)					183,505
Stock based compensation
Warrants issued	8,890				0	8,890
Net income (loss) for the period	-789,177						-789,177
Balance at Jun. 30, 2005	-759,034	0	0	0	426	29,717	-789,177
Balance (in shares) at Jun. 30, 2005		0	0	0	425,070
Issuance of preferred stock	198,866				0	198,866
Exercise of Warrant (April 2006) ($.001 per share)	100				2	98
Exercise of Warrant (April 2006) ($.001 per share) (in shares)					2,000
Excess of proceeds over fair value of Series B preferred	4,543,141				0	4,543,141
Stock based compensation
Net income (loss) for the period	-7,458,092						-7,458,092
Balance at Jun. 30, 2006	-3,475,019	0	0	0	428	4,771,822	-8,247,269
Balance (in shares) at Jun. 30, 2006		0	0	0	427,070
Excess of proceeds over fair value of Series B preferred	314,845				0	314,845
Conversion of Series B preferred shares into common shares upon merger (January 2007)	3,114,115				92	3,114,023
Conversion of Series B preferred shares into common shares upon merger (January 2007) (in shares)					91,862
Conversion of Series A preferred shares into common shares upon merger (January 2007)	2				3	-1
Conversion of Series A preferred shares into common shares upon merger (January 2007) (in shares)					2,577
Series B preferred dividend recorded as a capital contribution (January 2007)	387,104				0	387,104
Shares issued in conjunction with merger (January 2007)	7,020,000				180	7,019,820
Shares issued in conjunction with merger (January 2007) (in shares)					180,000
Reconversion of common shares back to Series B preferred shares (May 2007)	-3,114,115				-92	-3,114,023
Reconversion of common shares back to Series B preferred shares (May 2007) (in shares)					-91,862
Stock based compensation
- Clinical and Advisory Board	321,634				0	321,634
- Employees and Directors	462,156				0	462,156
- Executives	7,173,547				0	7,173,547
Net income (loss) for the period	-55,400,890						-55,400,890
Balance at Jun. 30, 2007	-43,196,621	0	0	0	611	20,450,927	-63,648,159
Balance (in shares) at Jun. 30, 2007		0	0	0	609,647
Shares issued as part of convertible promissory notes extension agreement (July 2007)	622,354				6	622,348
Shares issued as part of convertible promissory notes extension agreement (July 2007) (in shares)					6,230
Shares issued upon conversion of convertible promissory notes and accrued interest (July 2007)	31,733				0	31,733
Shares issued upon conversion of convertible promissory notes and accrued interest (July 2007) (in shares)					365
Shares issued as part of convertible promissory notes extension agreement (November 2007)	11,100				1	11,099
Shares issued as part of convertible promissory notes extension agreement (November 2007) (in shares)					600
Shares exchanged as part of convertible promissory notes extension agreement (February 2008)	-23,400				-1	-23,399
Shares exchanged as part of convertible promissory notes extension agreement (February 2008) (in shares)					-600
Shares reissued for issuance of convertible promissory note	-31,733				0	-31,733
Shares reissued For Issuance Of Convertible Promissory Note (in shares)					-365
Stock based compensation
- Clinical and Advisory Board	130,660				0	130,660
- Employees and Directors	736,370				0	736,370
Shares issued as part of a consulting agreement	120,000				1	119,999
Shares issued as part of a consulting agreement (in shares)					1,000
Net income (loss) for the period	19,625,103						19,625,103
Balance at Jun. 30, 2008	-21,974,434	0	0	0	618	22,048,004	-44,023,056
Balance (in shares) at Jun. 30, 2008		0	0	0	616,877
Stock based compensation
Stock based compensation	470,807				0	470,807
Net income (loss) for the period	1,846,763						1,846,763
Balance at Jun. 30, 2009	-19,656,864	0	0	0	618	22,518,811	-42,176,293
Balance (in shares) at Jun. 30, 2009		0	0	0	616,877
Stock based compensation
Stock based compensation	22,771				0	22,771
Sale of investment units	1,740,000				1,160	1,738,840
Sale of investment units (in shares)					1,160,000
Conversion of promissory notes and interest into common stock	8,067,872				4,261	8,063,611
Conversion of promissory notes and interest into common stock (in shares)					4,261,194
Conversion of royality notes and interest into common stock	6,791,057				2,865	6,788,192
Conversion of royality notes and interest into common stock (in shares)					2,865,374
Shares issued as part of consulting on the financing transaction agreement (April 2010)	0				946	-946
Shares issued as part of consulting on the financing transaction agreement (April 2010) (in shares)					946,000
Warrants issued	-5,570,897				0	-5,570,897
Shares issued as part of a consulting agreement	2,626,000				382	2,625,618
Shares issued as part of a consulting agreement (in shares)					381,583
Shares issued as a part of claim settlement	425,715				77	425,638
Shares issued as a part of claim settlement (in shares)					77,403
Shares issued to an officer	400,000				50	399,950
Shares issued to an officer (in shares)					50,000
Shares issued in settlement of prior debt	248,000				21	247,979
Shares issued in settlement of prior debt (in shares)					21,000
Cashless exercise of Warrants	15,625,441				1,765	15,623,676
Cashless exercise of Warrants (in shares)					1,765,240
Conversion of preferred stock and interest into common stock	2,016,510				4,139	2,012,371
Conversion of preferred stock and interest into common stock (in shares)					4,138,935
Net income (loss) for the period	-33,047,726						-33,047,726
Balance at Jun. 30, 2010	-20,312,120	0	0	0	16,284	54,895,614	-75,224,019
Balance (in shares) at Jun. 30, 2010		0	0	0	16,283,606
Issuance of preferred stock	2,185,384	22				2,185,362
Issuance of preferred stock (in shares)		22,000
Stock based compensation
Stock based compensation	241,969				1,345	240,624
Stock based compensation (in shares)					1,345,119
Conversion of promissory notes and interest into common stock	1,401,807				6,752	1,395,055
Conversion of promissory notes and interest into common stock (in shares)					6,751,747
Cashless exercise of Warrants	2,662,229				32,570	2,629,659
Cashless exercise of Warrants (in shares)					32,570,671
Exercise of Warrants for Cash	517,584				4,000	513,584
Exercise of Warrants for Cash (in shares)					4,000,000
Conversion of preferred stock and interest into common stock	749,500				5,800	743,700
Conversion of preferred stock and interest into common stock (in shares)					5,800,000
Deemed Preferred Stock Dividend	-950,000						-950,000
Net income (loss) for the period	140,573						140,573
Balance at Jun. 30, 2011	-13,363,074	22	0	0	66,751	62,603,599	-76,033,446
Balance (in shares) at Jun. 30, 2011		22,000	0	0	66,751,143
Stock based compensation
Stock based compensation	161,606				3,545	158,061
Stock based compensation (in shares)					3,545,000
Conversion of promissory notes and interest into common stock	25,000	0			500	24,500
Conversion of promissory notes and interest into common stock (in shares)		0			500,000
Cashless exercise of Warrants	144,074				3,444	140,630
Cashless exercise of Warrants (in shares)					3,443,877
Conversion of preferred stock and interest into common stock	55,476	-1			26,000	29,477
Conversion of preferred stock and interest into common stock (in shares)		-1,300			26,000,000
Net income (loss) for the period	1,896,990						1,896,990
Balance at Jun. 30, 2012	-11,079,928	21	0	0	100,240	62,956,267	-74,136,456
Balance (in shares) at Jun. 30, 2012		20,700	0	0	100,240,020
Stock based compensation
Stock based compensation	192,500				17,250	175,250
Stock based compensation (in shares)					17,250,000
Conversion of accrued Series C interest to Series C shares	840,000	1				839,999
Conversion of accrued Series C interest to Series C shares (in shares)		840
Cashless exercise of Warrants	411,615				29,526	382,089
Cashless exercise of Warrants (in shares)					29,525,879
Issuance of Series D preferred stock	2,442,897		7			2,442,890
Issuance of Series D preferred stock (in shares)			6,716
Issuance of Series E preferred stock	2,700,000			2		2,699,998
Issuance of Series E preferred stock (in shares)				2,000
Conversion of Series C preferred stock into common stock	0	-2			37,000	-36,998
Conversion of Series C preferred stock into common stock (in shares)		-1,750			37,000,000
Conversion of Series D preferred stock into common stock	0		-2		25,000	-24,998
Conversion of Series D preferred stock into common stock (in shares)			-1,250		25,000,000
Deemed Preferred Stock Dividend	700,000					700,000
Net income (loss) for the period	-9,055,510						-9,755,510
Balance at Jun. 30, 2013	($13,548,426)	$20	$5	$2	$209,016	$70,134,497	($83,891,966)
Balance (in shares) at Jun. 30, 2013		19,790	5,466	2,000	209,015,899

Consolidated_Statement_of_Chan1

Consolidated Statement of Changes in Capital Deficiency [Equity] [Parenthetical] (USD $)	12 Months Ended
	Jun. 30, 2006	Jun. 30, 2005
Equity Issuance Per Share Amount One		$0.00
Equity Issuance Per Share Amount Two		$0.00
Equity Issuance Per Share Amount Three	$0.00
Equity Issuance Per Share Amount Four	$0.00

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		98 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Cashflows from operating activities:
Net income (loss)	($9,755,510)	$1,896,990	($83,891,966)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	0		836,769
Amortization of financing costs	0		2,403,966
Change in unrealized gain of derivative instruments	-1,974,084	-7,194,320	-43,831,532
Stock and warrant based compensation	3,799,786	161,606	18,087,586
Interest expense related to warrants	3,029,911	2,376,123	44,419,043
Write-off of investment	0	0	150,000
Shares issued in connection with merger	0	0	7,020,000
Shares issued for note extensions and compensation	0	0	753,453
Conversion of common stock to new Series B preferred shares	0	0	6,606,532
Non-cash interest expense	3,651,997	3,203,958	20,114,258
Non-cash expense related to Series B dividends	0	0	1,802,611
Disposition of fixed assets	0	0	43,412
Loss on sale of fixed assets	0	0	179,516
Loss on extinguishment of debt	0	0	-74,060
Changes in:
Prepaid expenses and other assets	19,585	-20,385	-898
License fee receivable	0	0	-6,963
Accounts payable and accrued expenses	97,646	-435,838	3,439,494
Accrued interest		-71,152	0
Deferred lease liability	0	0	0
Other long term liabilities	0	0	-71,152
Net cash used in operating activities:	-1,130,669	-83,018	-22,019,932
Cashflows from investing activities:
Security deposit	0	0	-3,912
Acquisition of property and equipment	0	0	-1,059,699
Restricted cash	0	0	0
Cash paid for acquisition	0	0	-150,000
Net cash used in investing activities:	0	0	-1,213,611
Cashflows from financing activities:
Borrowings from stockholders	0	0	6,153,828
Proceeds from sale of common stock	0	0	1,761,353
Proceeds from sale of preferred stock	0	0	7,711,150
Preferred stock issuance costs	0	0	-814,550
Proceeds from sale of Convertible Promissory Notes	1,166,000	351,500	12,124,000
Repayment of borrowings from stockholder	0	0	-1,706,000
Convertible Promissory Notes issuance cost	0	0	-466,100
Repayment of borrowings from noteholders	-32,500	-367,500	-1,725,000
Proceeds from excersise of stock warrants	0	0	200,000
Net cash provided by (used in) financing activities:	1,133,500	-16,000	23,238,681
Net increase (decrease) in cash and cash equivalents	2,831	-99,018	5,138
Cash and cash equivalents beginning of period	2,307	101,325
Cash and cash equivalents end of period	5,138	2,307	5,138
Supplemental disclosure of cash flow informations:
Interest	0	73,378	145,115
Non-cash investing and financing transactions:
Conversion of Convertible Notes payable and accrued interest into Common Stock (including derivative liability)	0	25,000	16,285,736
Conversion of Preferred Stock to Common Stock	62,000	55,476	6,860,451
Common Stock issued in repayment of debt	0	0	248,000
Accrued dividend on Series B prefs treated as capital contribution	0	0	387,104
Cashless excersise of Warrant for Common Stock	411,615	144,074	18,843,360
Debt discount from warrants and beneficial conversion feature	890,697	351,500	1,542,197
Deemed preferred stock dividend from beneficial conversion feature	700,000	0	1,650,000
Issuance of warrants for repayment of accrued expenses	$560,000	$144,085	$704,085

Business_Description_and_Going

Business Description and Going Concern	12 Months Ended
	Jun. 30, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Business Description and Going Concern
	Intellect Neurosciences, Inc., a Delaware corporation, (“Intellect”, “our”, “us”, “we” or the “Company” refer to Intellect Neurosciences, Inc. and its subsidiaries) is a biopharmaceutical company, which together with its subsidiary, Intellect Neurosciences, USA, Inc. (“Intellect USA”), is engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of neurodegenerative conditions, collectively known as proteinopathies, which include Alzheimer’s (“AD”), Parkinson’s and Huntington disease. Since our inception in 2005, we have devoted substantially all of our efforts and resources to research and development activities and advancing our patent estate. We operate under a single segment. We have had no product sales from inception but we have received $10,516,667 in license fees from inception through June 30, 2013. Our losses from operations have been funded primarily with the proceeds of equity and debt financings and fees from license arrangements.
	We are a development stage company and our core business strategy is to build a portfolio of compounds with the potential to treat or prevent neurodegenerative diseases, develop each to pre-determined milestones, and license them to pharmaceutical companies for advanced development and commercialization. To supplement our own work, we intend to license promising novel technologies and early stage compounds from academia and other biotechnology companies. We intend to obtain revenues from licensing fees, milestone payments, development fees, royalties and/or sales related to the use of our drug candidates or intellectual property for specific therapeutic indications or applications.
	As of June 30, 2013, we had no self-developed or licensed products approved for sale by the U.S. Food and Drug Administration (“FDA”). There can be no assurance that our research and development efforts will be successful, that any products developed by any of our licensees will obtain necessary government regulatory approval or that any approved products will be commercially viable. In addition, we operate in an environment of rapid change in technology and are dependent upon the continued services of our current employees, consultants and subcontractors.
	One of our key assets is our ANTISENILIN patent estate. We have entered into two license agreements and one option agreement with major global pharmaceutical companies with respect to this patent estate. In addition, we have licensed OX1to ViroPharma Inc. (“ViroPharma”) who intend to develop and commercialize OX1 as a treatment for Friedreich’s Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation
	Our proprietary pipeline includes:
	OX1 – Licensed to ViroPharma, Inc.
	OX1 is an orally-administered, brain-penetrating, naturally-occurring copper-binding small molecule, which has the potential to treat various neurodegenerative diseases such as Friedreich's Ataxia, Parkinson’s and Wilson’s disease. OX1 was tested in human Phase I safety clinical trials involving 90 healthy elderly volunteers and was found to be well tolerated, even at high pharmacological doses. Our rights in the intellectual property underlying OX1 are licensed from New York University (“NYU”) and the University of South Alabama Medical Science Foundation (“SAMSF”).
	In September 2011, we granted an exclusive license to ViroPharma Incorporated (“ViroPharma”) regarding certain of our licensed patents and patent applications related to OX1. (See Material Agreements below.) ViroPharma expects to develop and commercialize OX1 as a treatment of Friedreich’s Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation. Friedreich's Ataxia is an inherited disease that causes progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems; it can also lead to heart disease and diabetes.
	CONJUMAB: NO1-OX2
	N01-OX2 is a first-in-class antibody drug conjugate for treatment of proteinopathies. It is a humanized monoclonal antibody specific for beta amyloid protein that has been empowered to deliver on-site neuroprotection by its conjugation to melatonin. Melatonin is a potent free radical scavenger and is recognized as an inhibitor of beta amyloid aggregation. N01-OX2 is designed to reduce oxidative stress and promote clearance of beta amyloid, which are central to cellular inflammation and damage. N01-OX2 utilizes a mouse antibody that we acquired from Immuno-Biological Laboratories Co., Ltd. (“IBL”), which was humanized by MRCT.
	OLIGOTOPE: TOC-01
	TOC -01 is a murine monoclonal antibody selective for tau oligomers. We plan to test TOC-01 as a potential therapeutic for Alzheimer’s disease and other tauopathies. The OLIOGOTOPE platform consists of protein oligomer selective antibodies and methods of making them using chemically cross-linked stabilized aggregates as antigens. Our rights in the intellectual property underlying TOC-01 are licensed from Northwestern University (“NWU”).
	RECALL VAX: RV03
	RV03 is a first-in-class bi-specific vaccine targeting both beta amyloid and delta tau. Delta tau is a shorter form of the tau protein. It is especially toxic to nerve cells and precedes the formation of neurofibrillary tangles. RV03 has potential for the treatment of Alzheimer’s disease and Frontotemporal dementias. The RECALL-VAX technology, invented by Dr. Benjamin Chain, Ph.D., (brother of Daniel Chain, our Chief Executive Officer and Chairman), has been assigned to us.
	These consolidated financial statements are presented on the basis that we will continue as a going concern. The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since our inception in 2005, we have generated losses from operations and we anticipate that we will continue to generate significant losses from operations for the foreseeable future. As of June 30, 2013, we had negative working capital of $12,321,404 and our deficit accumulated during the development stage was $83,891,966. We have primarily generated a loss from operations, the Company had an operating loss of $4,347,686 for the for the year ended June 30, 2013 compared to operating income for the year ended June 30, 2012 of $283,782. Our cash used in operations was $1,130,669 and $83,018 for the years ended June 30, 2013 and 2012, respectively. Our capital deficiency was $13,548,426 and $11,079,928 as of June 30, 2013 and 2012, respectively.
	We have limited capital resources and operations since inception have been funded with the proceeds from equity and debt financings and license fee arrangements. As of June 30, 2013, we had cash and cash equivalents of $5,138. In September 2011, we granted an exclusive license to ViroPharma regarding certain of our licensed patents and patent applications related to OX1 in exchange for payment by ViroPharma of a $6.5 million up-front licensing fee and additional regulatory milestone payments based upon defined events in the United States and the European Union.
	We anticipate that our existing capital resources will enable us to continue operations for the next two months. If we fail to raise additional capital or obtain substantial cash inflows from existing or potential partners within the next month, we may be forced to cease operations. We cannot assure you that financing will be available in a timely manner, on favorable terms or at all.
	On April 12, 2011, we completed a 50 to1 reverse stock split. The accompanying financial statements and notes to the financial statements presented herein give retroactive effect to the reverse split for all periods presented.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies
	Principles of Consolidation. The consolidated financial statements include the accounts of our wholly owned subsidiary, Intellect Israel, and the accounts of Mindgenix, Inc. (“Mindgenix”), a wholly-owned subsidiary of Mindset Biopharmaceuticals, Inc. (“Mindset”). We consolidate Mindgenix because we have agreed to absorb certain costs and expenses incurred by Mindgenix that are attributable to its research. Dr. Chain, our CEO, is a controlling shareholder of Mindset and the President of Mindgenix. All inter-company transactions and balances have been eliminated in consolidation.
	Use of Estimates. The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates include the fair value of derivative instruments, including stock options and warrants to purchase our common stock, recognition of clinical trial costs, certain consulting expenses and deferred taxes. Actual results may differ substantially from these estimates.
	Stock-Based Compensation. We recognize compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, we calculate the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, we calculate the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
	Research and Development Costs and Clinical Trial Expenses. Research and development costs include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses, the full cost of manufacturing drugs for use in research, preclinical development, and clinical trials. All costs associated with research and development are expensed as incurred.
	Revenue Recognition. We recognize revenue in accordance with authoritative accounting guidance, which provides that non-refundable upfront and research and development milestone payments and payments for services are recognized as revenue as the related services are performed over the term of the collaboration.
	Convertible Instruments We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
	We account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. We also record when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
	Common Stock Purchase Warrants We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess classification of our common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
	Preferred Stock. We apply the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity” when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders’ equity.
	Derivative Instruments. Our derivative financial instruments consist of embedded derivatives related to the convertible debt, warrants and beneficial conversion features embedded within our convertible debt. The accounting treatment of derivative financial instruments requires that we record the derivatives and related warrants at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each balance sheet date. If the fair value of the derivatives was higher at the subsequent balance sheet date, we recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, we recorded non-operating, non-cash income.
	During the years ended June 30, 2013 and 2012, we recognized other income of approximately $2.5 million and $7.2 million, respectively, relating to recording the derivative liabilities at fair value. At June 30, 2013 and 2012 there were approximately $2.6 million and $3.4 million of derivative liabilities.
	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the year ended June 30, 2013:
	Estimated dividends	None
	Expected volatility	331%
	Risk-free interest rate	1.45%
	Expected term (years)	1.0 - 5.0 years
	Fair value of financial instruments. We adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.
	The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.
	ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	We measure derivative liabilities at fair value using the Black-Scholes option pricing model with assumptions that include the fair value of the stock underlying the derivative instrument, the exercise or conversion price of the derivative instrument, the risk free interest rate for a term comparable to the term of the derivative instrument and the volatility rate and dividend yield for our common stock. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has not paid dividends to date and does not expect to pay dividends in the foreseeable future due to its substantial accumulated deficit. Accordingly, expected dividends yields are currently zero. Expected volatility is based principally on an analysis of historical volatilities of similarly situated companies in the marketplace for a number of periods that is at least equal to the contractual term or estimated life of the applicable financial instrument.
	We also considered the use of the lattice or binomial models with respect to valuing derivative financial instruments that feature anti-dilution price protection; however, the differences in the results are insignificant due to the low probability of triggering price adjustments in such financial instruments.
	Income taxes. We use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.
	ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.
	Net Loss Per Share. Basic net income or basic net loss per common share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options, convertible debt, and convertible preferred stock are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.
	New Accounting Pronouncements
	In May 2011, the FASB issued ASU 2011-04, “Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS” (“ASU 2011-04”). The amendments in ASU 2011-04 result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, ASU 2011-04 changes the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, the FASB does not intend for the amendments in ASU 2011-04 to result in a change in the application of the requirements in Topic 820. ASU 2011-04 is effective prospectively for interim and annual reporting periods beginning after December 15, 2011. This ASU will become effective for the company beginning in the quarter ended January 31, 2012 and we do not expect an impact on our consolidated financial statements
	In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. The guidance in ASU 2011-05 applies to both annual and interim financial statements and eliminates the option for reporting entities to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. This ASU also requires consecutive presentation of the statement of net income and other comprehensive income. Finally, this ASU requires an entity to present reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this ASU should be applied retrospectively and are effective for fiscal year, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial position or results of operations.

Material_Agreements

Material Agreements	12 Months Ended
	Jun. 30, 2013
Material Agreements [Abstract]
Material Agreements Disclosure [Text Block]	Note 3. Material Agreements
	Mindset Asset Transfer Agreement. The majority of Intellect’s assets were acquired in 2005 from Mindset Biopharmaceuticals, Inc., which we refer to as “Mindset”. Dr. Daniel Chain, our Chairman and Chief Executive Officer, founded Mindset and remains a significant stockholder of Mindset. He had previously served as Mindset’s Chairman and Chief Executive Officer, and currently serves as its President. Dr. Chain spends approximately 5% of his time on matters relating to Mindset. Mindset is not involved in any business that competes, directly or indirectly, with the business of Intellect. Mindset’s current business plan is to leverage its intellectual property estate through licenses and other arrangements and to provide transgenic mice for Alzheimer’s disease research through its existing subsidiary, Mindgenix, Inc.
	Research and License Agreements (“RLAs”) with South Alabama Medical Science Foundation (“SAMS”) and New York University (“NYU”). Effective August 1998, and as amended, Mindset entered into RLAs with SAMS and NYU. In June 2005, SAMS and NYU consented to Mindset's assignment of the RLAs to us. Under the RLAs, we have an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain patents and know-how relating to the use of indole-3-propionic acid among other things, to prevent Alzheimer’s Disease (“AD”). We are obligated to make future payments to SAMS and NYU totaling approximately $3,000,000 upon achievement of certain milestones based on phases of clinical development and approval of the FDA (or foreign equivalent) and also to pay SAMS and NYU royalties on net sales (as defined) attributable to each product utilizing the licensed technology. In September 2011, we granted a sublicense of the RLAs to ViroPharma pursuant to which we received a $6.5 million up-front licensing fee and are entitled to receive additional regulatory milestone payments based upon defined events in the United States and the European Union. Pursuant to the terms of the RLAs, we have paid each of SAMS and NYU $650,000 of the up-font licensing fee and are required to pay a portion of future payments we may receive from ViroPharma. (See ViroPharma License Agreement below.)
	Chimeric Peptide Assignment Agreement. Effective as of June 6, 2000, Dr. Benjamin Chain assigned to Mindset all of his right, title and interest in certain of his inventions and patent applications related to the use of chimeric peptides for the treatment of AD. Dr. Benjamin Chain is the brother of our Chairman and Chief Executive Officer. In exchange for such assignment, Mindset agreed to pay a royalty to Dr. Benjamin Chain equal to 1.5% of net sales of any drug products sold or licensed by Mindset utilizing the chimeric peptide technology. We acquired these inventions and patent applications and are obligated to make royalty payments to Dr. Benjamin Chain upon successful development of a drug utilizing this chimeric peptide technology. We have yet to develop any drug product that would trigger our obligation to make future payments to Dr. Benjamin Chain.
	Beta-Amyloid Specific, Humanized Monoclonal Antibody Purchase and Sale Agreement. Under the terms of a Beta-Amyloid Specific, Humanized Monoclonal Antibody Purchase and Sale Agreement (the "IBL Agreement") with Immuno-Biological Laboratories Co., Ltd. ("IBL"), we acquired two beta amyloid specific monoclonal antibodies ready for humanization, and the IBL patents or applications relating to them. In consideration, we agreed to pay IBL a total of $2,125,000 upon the achievement of certain milestones plus a specified royalty based on sales of any pharmaceutical product derived from the antibodies. Also, we granted to IBL a worldwide, exclusive, paid-up license under certain of our granted patents and pending applications in Japan. The IBL Agreement expires upon the last to expire of the relevant Intellect patents, unless earlier terminated as the result of a material breach by or certain bankruptcy related events of either party to the agreement.
	Research Collaboration Agreement with MRC Technology (“MRCT”). We entered into a Research Collaboration Agreement with MRCT pursuant to which MRCT agreed to conduct a project to humanize one of our beta-amyloid specific, monoclonal antibodies for the treatment of AD. We are obligated to pay MRCT a total of $200,000 of up-front fees and $560,000 of research milestone payments related to the development of the humanized antibody and additional commercialization milestones and sales based royalties related to the resulting drug products. Under the agreement as amended, we may deliver warrants to purchase our common stock as payment for the $560,000 in research milestones under certain circumstances related to our future financing activities. Three of the five research milestones have been achieved and as a result, a liability of $350,000 reflecting research milestone payment obligations outstanding is included in Accounts Payable and Accrued Expenses. No additional work was performed and no additional liabilities were incurred during the fiscal year ended June 30, 2013. On September 16, 2012 the Company issued to MRCT 11,200,000 warrants with an exercise price of $0.0625 in full consideration for the money owed to MRCT.
	Élan Pharma International Limited and Wyeth License Agreement. In May 2008, we entered into a License Agreement with AHP Manufacturing BV, acting through its Wyeth Medica Ireland Branch, (“Wyeth”) and Elan Pharma International Limited (“Elan”) to provide Wyeth and Elan (collectively, the “Licensees”) with certain license rights under certain of our patents and patent applications (the “Licensed Patents”) relating to certain antibodies that may serve as potential therapeutic products for the treatment for AD (the “Licensed Products”).
	We granted the Licensees a non-exclusive license under the Licensed Patents to research, develop, manufacture and commercialize Licensed Products. We received an upfront payment of $1 million in May 2008 and an additional $1 million in August 2008. We are eligible to receive certain milestones and royalties based on sale of Licensed Products.
	The Licensees have an option to receive ownership of the Licensed Patents if at any time during the term we abandon all activities related to research, development and commercialization of our products that are covered by the Licensed Patents and no other licenses granted by us under the Licensed Patents remain in force. Failure to incur $50,000 in patent or program research related expenses during any six month period is considered to be abandonment. We initially recorded the up-front payment of $1 million that we received from the Licensees in May 2008 as a deferred credit, representing our obligation to fund such future patent or program research related expenses, and we recorded periodic amortization expense related to the deferred credit based on the remaining life of the License. As described more fully below, we granted a license under the Licensed Patents to another pharmaceutical company in December 2008 and reclassified the balance of the deferred credit as revenue because the grant of the second license removed the requirement contained in the abandonment clause in this Agreement. We accounted for the payment received in August 2008 as revenue in the period of receipt.
	ANTISENILIN Option and License Agreement. In October 2008, we entered into an Option Agreement with a global pharmaceutical company (“Option Holder”) regarding an option to obtain a license under certain of our patents and patent applications (the “Subject Patents”) related to antibodies and methods of treatment for AD and to make, have made, use, sell, offer to sell and import certain Licensed Products, as defined in this agreement.
	We granted the Option Holder an irrevocable option to acquire a non-exclusive, royalty bearing license under the Subject Patents . In consideration, the Option Holder paid us a non-refundable fee of $500,000 and agreed to pay us $2,000,000 upon exercise of the option (the “Exercise Fee”). We are entitled to receive an additional $2,000,000 upon the grant in the United States of a Licensed Patent with at least one Valid Claim that covers a Licensed Product in the Territory in the Field (as such terms are defined in this agreement). An additional milestone payment shall be made to us should the Option Holder achieve certain thresholds for aggregate annual net sales. The agreement also provides that we will be eligible to receive certain royalty payments from the Option Holder in connection with net sales.
	In December 2008, the Option Holder exercised the option and paid us $1,550,000, which is the Exercise Fee, as adjusted.
	GSK Option and License Agreement. In April 2009, we entered into an Option Agreement with Glaxo Group Limited (“GSK”) regarding an option to purchase a license under certain of our patents and patent applications (the “GSK Patents”) related to antibodies and methods of treatment for AD. We granted GSK an irrevocable option to acquire a non-exclusive, royalty bearing license under the GSK Patents with the right to grant sublicenses, to develop, have developed, make, have made, use, offer to sell, sell, import and have imported Licensed Products.
	Upon exercise of the option, GSK will pay us $2,000,000 and, upon the later to occur of the exercise of the option by GSK and grant to us in the United States of a Licensed Patent with at least one Valid Claim that covers a Licensed Product incorporating a GSK Compound, GSK will pay us an additional $2,000,000. An additional milestone payment will be made to us should GSK achieve certain thresholds of annual net sales. This agreement also provides that we will be eligible to receive certain royalty payments from GSK in connection with net sales.
	ViroPharma License Agreement. On and effective as of September 29, 2011, we entered into an Exclusive License Agreement (the “License Agreement”) with ViroPharma, pursuant to which, among other things we granted an exclusive license to ViroPharma regarding certain of our licensed patents and patent applications related to OX1. ViroPharma expects to develop and commercialize OX1 as a treatment of Friedreich’s Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.
	Under the terms of the License Agreement, we have agreed to transfer to ViroPharma all of our intellectual property rights, data and know-how related to our OX1 research and development program in exchange for payment by ViroPharma of a $6.5 million up-front licensing fee and additional regulatory milestone payments based upon defined events in the United States and the European Union. The aggregate maximum of these milestone payments assuming successful advancement of the product to market could amount to $120 million. In addition, ViroPharma will pay us a tiered royalty of up to an aggregate maximum of low double digits based on annual net sales. NYU School of Medicine and South Alabama Medical Science Foundation, which own certain patents in relation to OX1, are entitled to a portion of the royalties and revenues received by us from any sale or license of OX1 pursuant to the RLAs described above.
	The term of the License Agreement will continue in effect on a licensed product-by-licensed product and country-by-country basis until the expiration of the last royalty obligation with respect to a licensed product in such country. Once the royalty obligation has terminated in a particular country, the license will become non-exclusive and fully paid-up with respect to licensed products in that country.
	Either party may terminate the License Agreement upon an uncured material breach of the other party. In addition, if ViroPharma determines that it is not feasible or desirable to develop or commercialize licensed products, it may terminate the License Agreement in whole or on a product-by-product basis at any time upon ninety (90) days prior written notice to the Company. In the event of a termination of the License Agreement, other than ViroPharma’s termination of the License Agreement for the Company’s uncured material breach, we will have an exclusive, perpetual, irrevocable, worldwide, royalty-bearing license to exploit the licensed products.
	License Agreement with Northwestern University (“NWU”). Effective May 2012, we entered into a License Agreement (“License”) with NWU pursuant to which we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain patents and know-how relating to the use of monoclonal antibody Tau C3 and TOC-1 for the prophylaxis, mitigation, diagnosis and/or treatment of AD and other tauopathies. We are obligated to make future payments to NWU totaling approximately $700,000 upon achievement of certain milestones based on phases of clinical development and also to pay NWU royalties on net sales (as defined) attributable to each product utilizing the licensed technology.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Jun. 30, 2013
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 4. Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consist of the following:
		June 30, 2013		June 30, 2012
	Professional Fees	$	1,080,675	$	1,160,080
	Consulting Expenses		853,197		733,197
	Clinical Expenses		206,890		766,890
	Other		346,648		289,597
	Total	$	2,487,410	$	2,949,764

Notes_Payable

Notes Payable	12 Months Ended
	Jun. 30, 2013
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 5. Notes Payable
	The “April 2010 Notes”
	On April 23, 2010, we issued Convertible Promissory Notes (the “April 2010 Notes”) with an aggregate principal amount of $580,000. The April 2010 Notes carry interest at 14% annually (payable in arrears) and mature three years from the issue date.
	We determined the initial fair value of the Warrants issued with the April 2010 Notes to be $41,093,377 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the April 2010 Notes. Under authoritative guidance, the carrying value of the April 2010 Notes may not be reduced below zero. Accordingly, we recorded the excess of the value of the Warrants over the face amount of the April 2010 Notes as interest expense incurred at the time of issuance of the April 2010 Notes. The face amount of the April 2010 Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	On November 3, 2010, we borrowed an additional $150,000 from certain holders of the April 2010 Notes and evidenced such borrowing by adding an addendum to the April 2010 Notes whereby the aggregate principal amount of such holders’ Notes was increased by $150,000. As partial consideration for the loan, we reduced the conversion price of such holders’ Notes from $1.50 to $0.125 per common share. As a result of the “ratchet” provisions contained in the April 2010 Notes and outstanding Warrants, the conversion price of the remaining outstanding April 2010 Notes and exercise price of our outstanding Warrants were adjusted to $0.125 per common share. The conversion price of previously issued and outstanding Series B Convertible Preferred Stock held by holders other than the purchasers is not subject to adjustment as a result of revisions to the April 2010 Notes.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The December 2010 Notes
	On December 15, 2010, we sold investment units for an aggregate purchase price of $500,000. Each unit consisted of a Convertible Promissory Note (the “December 2010 Notes”), shares of Series C Convertible Preferred Stock (“Series C Prefs”) and warrants (the “December 2010 Warrants”). Total proceeds from the sale of these investment units were $500,000.
	The December 2010 Notes have an aggregate face amount of $500,000, are due on December 15, 2013 and bear interest at 14%, payable at maturity. Principal and accrued interest on the Notes are convertible into shares of our common stock at an initial conversion price of $.125 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Notes. As a result of the ratchet provisions contained in the Notes, the holders are entitled to purchase up to 10 million shares of our Common Stock.
	The December 2010 Warrants initially entitle the holders to purchase up to a total of 4 million shares of our common stock at an initial exercise price of $0.125 per share. As a result of the ratchet provisions contained in the December 2010 Warrants, the holders are entitled to purchase up to 10 million shares of our Common Stock at an exercise price of $0.001 per share. Also, we issued an aggregate of 10,000 shares of Series C Prefs with an initial aggregate liquidation preference equal to $10 million, which, as a result of the ratchet provisions contained in the Certificate of Designation of series C Preferred Stock, are convertible into 200 million shares of our Common Stock at a conversion price of $0.05 per share.
	We allocated the $500,000 of proceeds to the December 2010 Notes and Series C Preferred shares based on their relative fair values at date of issuance, which resulted in an allocation of $25,000 and $475,000, respectively. We determined the initial fair value of the December 2010 Warrants to be $378,017 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the December 2010 Notes. Under authoritative guidance, the carrying value of the December 2010 Notes may not be reduced below zero. Accordingly, we recorded the excess of the value of the December 2010 Warrants over the allocated fair value of the December 2010 Notes as interest expense incurred at the time of issuance of the December 2010 Notes in the amount of $353,017. The discount related to of the December 2010 Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	The guidance provided in ASC 470-20-30-5 has been applied to the amount allocated to the Series C Preferred Stock, and the effective conversion price has been used to measure the intrinsic value of the embedded conversion option, and limited to the amount of proceeds allocated to the convertible instrument. The intrinsic value of the beneficial conversion feature was calculated by comparing the effective conversion price and the market price of the Company’s common stock on the date of issuance. The fair value of $475,000 of the beneficial conversion feature has been recognized as a deemed dividend on the preferred stock for the year ended June 30, 2011, since the Series C Preferred stock is immediately convertible upon issuance and has no stated redemption date.
	As a result of the “ratchet” provisions contained in the April 2010 Notes and outstanding Warrants, the conversion price of the remaining outstanding April 2010 Notes and exercise price of our outstanding Warrants and Series B Convertible Preferred Stock were adjusted to $0.001 per common share. The conversion price of previously issued and outstanding Series B Convertible Preferred Stock held by holders other than the purchasers of the April 2010 Notes is not subject to adjustment as a result of the issuance of the December 2010 Notes.
	In January 2011, as a result of the “ratchet” provisions contained in the April 2010 Notes, we issued to purchasers of the April 2010 Notes remaining outstanding an additional 2,000 shares of our Series C Prefs with an initial aggregate liquidation preference equal to $2 million, which are convertible into 40 million shares of our common stock at an exercise price of $0.001 per share. In addition, in May 2011, we issued 429,000 shares of our Common Stock as additional compensation to certain holders of the April 2010 Notes as a result of the “ratchet” provisions contained in those Notes.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The “March 2011 Notes”
	On March 15, 2011, we sold investment units for an aggregate purchase price of $500,000. Each unit consisted of a Convertible Promissory Note (the “March 2011 Notes”), shares of Series C Prefs and warrants (the “March 2011 Warrants”). Total proceeds from the sale of these investment units were $500,000. The terms of the March 2011 Notes and Warrants are the same as the terms contained in the December 2010 Notes and Warrants.
	The March 2011 Notes have an aggregate face amount of $500,000, are due on March 15, 2014 and bear interest at 14%, payable at maturity. Principal and accrued interest on the Notes are convertible into shares of our common stock at an initial conversion price of $.125 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Notes. As a result of the ratchet provisions contained in the March 2011Notes, the holders are entitled to purchase up to 10 million shares of our Common Stock.
	The March 2011 Warrants initially entitle the holders to purchase up to a total of 4 million shares of our common stock at an initial exercise price of $0.125 per share. As a result of the ratchet provisions contained in the March 2011 Warrants, the holders are entitled to purchase up to 10 million shares of our Common Stock at an exercise price of $0.001 per share. Also, we issued an aggregate of 10,000 shares of Series C Prefs with an initial aggregate liquidation preference equal to $10 million, which, as a result of the ratchet provisions contained in the Certificate of Designation of series C Preferred Stock, are convertible into 200 million shares of our Common Stock at a conversion price of $0.001 per share.
	We allocated the $500,000 of proceeds to the March 2011 Notes and Series C Prefs based on their relative fair values at date of issuance, which resulted in an allocation of $25,000 and $475,000, respectively. We determined the initial fair value of the March 2011 Warrants to be $378,017 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the March 2011 Notes. Under authoritative guidance, the carrying value of the March 2011 Notes may not be reduced below zero. Accordingly, we recorded the excess of the value of the March 2011Warrants over the allocated fair value of the March 2011 Notes as interest expense incurred at the time of issuance of the March 2011 Notes in the amount of $353,017. The discount related to of the March 2011 Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	The guidance provided in ASC 470-20-30-5 has been applied to the amount allocated to the Series C Preferred Stock, and the effective conversion price has been used to measure the intrinsic value of the embedded conversion option, and limited to the amount of proceeds allocated to the convertible instrument. The intrinsic value of the beneficial conversion feature was calculated by comparing the effective conversion price and the market price of the Company’s common stock on the date of issuance. The fair value of $475,000 of the beneficial conversion feature has been recognized as a deemed dividend on the preferred stock for the year ended June 30, 2011, since the Series C Preferred stock is immediately convertible upon issuance and has no stated redemption date.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The “June and July 2011 Notes”
	On June 30, 2011, we sold investment units (“June 2011 Investment Units”) for an aggregate purchase price of $100,000. Each unit consisted of a Convertible Promissory Note (the “June 2011 Notes”) and warrants (the “June 2011 Warrants”). Total proceeds from the sale of these investment units were $100,000.
	The June 2011 Notes have an aggregate face amount of $100,000, are due on June 30, 2014 and bear interest at 14%, payable at maturity. Principal and accrued interest on the June 2011 Notes are convertible into shares of our common stock at an initial conversion price of $.05 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the June 2011 Notes. The June 2011 Warrants entitle the holders to purchase up to a total of 10 million shares of our Common Stock at an initial exercise price of $0.05 per share.
	We determined the initial fair value of the June 2011 Warrants to be $817,151 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the June 2011 Notes by $100,000 with the excess of $717,151 charged to interest expense. This difference was amortized over the term of the June 2011 Notes as interest expense, calculated using an effective interest method.
	During July and August, 2011, we sold additional investment units for an aggregate purchase price of $150,000. Each unit consisted of a Convertible Promissory Note (the “July 2011 Notes”) and warrants (the “July 2011 Warrants”). Total proceeds from the sale of these investment units were $150,000.
	The June 2011 Notes issued in July have an aggregate face amount of $150,000, are due on various dates during July and August, 2014 and bear interest at 14%, payable at maturity. Principal and accrued interest on the July 2011 Notes are convertible into shares of our common stock at an initial conversion price of $.05 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Notes. The July 2011 Warrants entitle the holders to purchase up to a total of 20 million shares of our Common Stock at an initial exercise price of $0.05 per share.
	We determined the initial fair value of the July 2011 Warrants to be $1,626,973 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the July 2011 Notes by $150,000 with the excess of $1,476,973 charged to interest expense.
	In April 2012, we issued 500,000 shares of our common stock to one of the holders of July 2011 Notes upon his conversion of $25,000 principal amount due with respect to such Notes (Note 11.)
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The “April and May 2012” Financing
	During April and May 2012, we sold investment units for an aggregate purchase price of $201,500. Each unit consisted of a Convertible Promissory Note (the April and May 2012 Notes”) and warrants (the “April and May 2012 Warrants”). Total proceeds from the sale of these investment units were $201,500.
	The April and May 2012 Notes have an aggregate face amount of $201,500, are due in April and May 2015 and bear interest at 14%, payable at maturity. Principal and accrued interest are convertible into shares of our common stock at an initial conversion price of $0.05 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalent by us at a price less than the effective conversion price of the April 2012 Notes. The April and May 2012 Warrants entitle the holders to purchase up to 25,150,000 shares of our Common Stock at an initial exercise price of $0.05 per share.
	We determined the initial fair value of the April and May 2012 warrants to be $1,100,650 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the April and May 2012 Notes by $201,500 with the excess of $899,150 charged to interest expense. The discount related to the April and May 2012 Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	During July through November 2012, we sold additional investment units for an aggregate purchase price of $662,500. Each unit consisted of a Convertible Promissory Note and Warrants. Total proceeds from the sale of these investment units were $662,500.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	January 2013 Financing
	During January, February, March, May and June 2013, we sold investment units for an aggregate purchase price of $372,500. Each unit consisted of a Convertible Promissory Note (the January 2013 Notes”) and warrants (the “January 2013 Financing Warrants”). Total proceeds from the sale of these investment units were $503,500.
	The January 2013 Notes have an aggregate face amount of $503,500, are due in January, February, March, May and June 2016 and bear interest at 14%, payable at maturity. Principal and accrued interest are convertible into shares of our common stock at an initial conversion price of $0.01 per share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalent by us at a price less than the effective conversion price of the April 2012 Notes. The January 2013 Financing Warrants entitle the holders to purchase up to 247,500,000 shares of our Common Stock at an initial exercise price of $0.01 per share.
	We determined the initial fair value of the January 2013 Financing warrants to be $2,400,728 based on the Black-Scholes option pricing model, which we treated as a liability with a corresponding decrease in the carrying value of the January 2013 Financing Notes by $503,500 with the excess of $2,028,228 charged to interest expense. The discount related to the January 2013 Financing Notes will be amortized over the term of the notes as interest expense, calculated using an effective interest method.
	The Company has determined that the conversion feature embedded in the convertible notes constitute a derivative and have been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt or a charge to interest expense where the derivative exceeds the carrying value of the note, on the accompany balance sheet, and revalued to fair market value at each reporting period.
	The following table sets forth a summary of all of the outstanding convertible promissory notes at June 30, 2013:
	Convertible promissory notes issued	$	3,657,500
	Allocated to preferred stock		-256,203
	Notes repaid		-400,000
	Less amounts converted to common stock		-625,000
			2,376,297
	Less debt discount		1,144,560
	Balance June 30, 2013	$	1,231,737

Series_B_Convertible_Preferred

Series B Convertible Preferred Stock and Derivative Liability	12 Months Ended
	Jun. 30, 2013
Series B Convertible Preferred Stock and Derivative Liability [Abstract]
Series B Convertible Preferred Stock and Derivative Liability Disclosure [Text Block]	Note 6. Series B Convertible Preferred Stock and Derivative Liability
	Series B Convertible Preferred Stock
	During the fiscal year ended June 30, 2007, we issued 459,309 shares of Series B Convertible Preferred Stock (the “Series B Prefs”). The shares carry a cumulative dividend of 6% per annum. The initial conversion price is 1.75 per share subject to certain anti-dilution adjustments. Each Series B Preferred share carries a stated value of $17.50 and is convertible into 10 shares of our Common Stock. We issued 3,046,756 warrants in connection with the issuance of the Series B Prefs (the “Series B Warrants”).
	Based on authoritative guidance, we accounted for the Series B Prefs and the Series B Warrants as derivative liabilities at the time of issuance using the Black Scholes option pricing model. We recorded the amount received in consideration for the Series B Prefs as a liability for the Series B Prefs with an allocation to the Series B Warrants and the difference recorded as additional paid in capital. The liability related to the Series B Prefs and the Series B Warrants will be marked to market for all future periods they remain outstanding with an offsetting charge to earnings.
	At June 30, 2013, the aggregate liquidation value of the Series B Prefs was $1,870,380, with a fair value of $172,874. As of June 30, 2013, we have accrued Series B Preferred Stock dividends payable of $576,934 which has been recognized as interest expense.
	As a result of the “ratchet” provisions contained in the Certificate of Designation of the Series B Prefs, the conversion price of the remaining Series B Prefs, as subsequently amended by a majority in interest of the holders of the series B Prefs, was reduced to $0.05 per common share as a result of the December
	2010 Financing transaction described above. The conversion price of previously issued and outstanding Series B Prefs held by holders other than the purchasers of the April 2010 Notes is not subject to adjustment as a result of the issuance of the December 2010 Notes or March 2011 Notes.
	Series C Convertible Preferred Stock
	Effective December 15, 2010, our Board of Directors approved a Certificate of Designation of Series C Convertible Preferred Stock. Each share of Series C Convertible Preferred Stock carries a stated value of $1,000 and a conversion price of $0.05 per common share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Series C Preferred Stock. We issued to the purchasers of the December 2010 Notes 12,000 shares of our Series C Convertible Preferred Stock with an initial aggregate liquidation preference equal to $12 million, which are convertible into 240 million shares of our common stock.
	On March 15, 2011, we issued to certain purchasers of the March 2011 Notes an additional 10,000 shares of our Series C Convertible Preferred Stock with an initial aggregate liquidation preference equal to $10 million, which are convertible into 200 million shares of our common stock, in exchange for $500,000 (Note 5).
	During the year ended June 30, 2013, we issued 37,000,000 shares of our common stock to holders of Series C Preferred upon conversion of their shares.
	Series D Convertible Preferred Shares
	Effective October 24, 2010, our Board of Directors approved a Certificate of Designation of Series D Convertible Preferred Stock. Each share of Series D Convertible Preferred Stock carries a stated value of $1,000 and a conversion price of $0.05 per common share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Series D Preferred Stock. The Series D Preferred Stock was issued to holders of our warrants in exchange for cancellation of those warrants. The number of shares of Series D Preferred Stock issued to each warrant holder is an amount equal to the number of Series D Preferred Shares that would be convertible into an amount of common shares equal to 50% of the number of warrants held by such holder. Based on this formula, we issued 6,716 shares of Series D Preferred stock, which are convertible into 134,320,000 shares of our common stock.
	During the year ended June 30, 2013, we issued 25,000,000 shares of our common stock to holders of Series D Preferred upon conversion of their shares.
	Series E Convertible Preferred Shares
	Effective January 2, 2013, our Board of Directors approved a Certificate of Designation of Series E Convertible Preferred Stock. Each share of Series E Convertible Preferred Stock carries a stated value of $1,000 and a conversion price of $0.01 per common share, subject to customary anti-dilution protection in the case of stock dividends, stock splits, reverse splits, reorganizations and recapitalizations and subject to full ratchet protection in the case of any sale of common stock or common stock equivalents by us at a price less than the then effective conversion price of the Series E Preferred Stock. The Series E Preferred Stock was issued to holders of royalty rights with respect to the Company’s anti-senilin patent estate (the “Royalty Rights”) in exchange for the Royalty Rights held by them. On January 2, 2013, we issued 2,000 shares of Series E Preferred stock, which are convertible into 200,000,000 shares of our common stock.
	The Company recognized this difference between the fair value per share of its common stock and the conversion price, multiplied by the number of shares issuable upon conversion. This Beneficial Conversion Feature of $700,000 was recorded as additional paid-in-capital for common shares, per EITF 98-5 “Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios”. The offsetting amount was amortizable over the period from the issue date to the first conversion date. Since the Series E Preferred Stock is immediately convertible, a deemed dividend of $700,000 to the Series E Preferred Stock was recorded and immediately amortized. As the Company is in an accumulated deficit position, the deemed dividend was charged against additional paid-in-capital for common shares, there being no retained earnings from which to declare a dividend. The net income (loss) attributable to common shareholders reflects both the net income (loss) and the deemed dividend

Outstanding_Warrants_and_Warra

Outstanding Warrants and Warrant Liability	12 Months Ended
	Jun. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	Note 7. Outstanding Warrants and Warrant Liability
	The “2006 Warrants”
	In connection with the sale of the 2006 Notes, we issued warrants (the “2006 Warrants”), entitling the holders to purchase up to 43,428 shares of our common stock. We issued additional 2006 Warrants upon extension of the maturity date of certain of the 2006 Notes. The 2006 Warrants expire five years from date of issuance, except for 22,857 of such warrants, which expire in 2013. The number of shares underlying each 2006 Warrant is the quotient of the face amount of the related 2006 Note divided by 50% of the price per equity security issued in the Next Equity Financing, which occurred on May 12, 2006. The 2006 Warrant exercise price is 50% of the price per equity security issued in the Next Equity Financing. The maximum number of shares available for purchase by an investor is equal to the principal amount of such holder's 2006 Note divided by the warrant exercise price.
	As of May 2013, all of the 2006 Warrants expired without being exercised.
	The “Convertible Note Warrants”
	In connection with the sale of the 2007 and 2008 Notes, we issued 76,751 and 3,714 warrants, respectively. In addition, we issued 7,429 warrants in connection with a Convertible Note issued during fiscal year ended June 30, 2009 (the “Convertible Note Warrants”).
	The Convertible Note Warrants expire five years from date of issuance. The number of shares underlying each Convertible Note Warrant is the quotient of the face amount of the related Note divided by 87.5. The exercise price of each warrant is $87.50 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the Warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans). The terms of the Warrants fail to specify a penalty if we fail to satisfy our obligations under these piggyback registration rights. Presumably, we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for the Convertible Note Warrants as liabilities. The liability for the Convertible NoteWarrants, measured at fair value, based on a Black-Scholes option pricing model, has been offset by a reduction in the carrying value of the related Notes. These warrants expired without being exercised in February 2012.
	In connection with the Convertible Note Financing, we issued 28,464 warrants to the placement agent. Based on authoritative guidance, we have accounted for these warrants as liabilities. The liability, measured at fair value on the date of issuance using a Black-Scholes option pricing model, will be marked to market for each future period the warrants remain outstanding. As of June 30, 2013, all of these warrants remain outstanding, with an exercise price of $0.05 per share.
	The “Royalty Warrants”.
	In connection with the issuance of the Royalty Notes, we issued warrants to purchase up to 65,429 of our common shares (the “Royalty Warrants”). We issued approximately 7,429 warrants to the lender who advanced to us new funds of $650,000 and issued the remaining 58,000 warrants to the other lenders who exchanged their notes for Royalty Notes. The Royalty Warrants contain the same terms as the Convertible Note Warrants described above.
	Based on authoritative guidance, we accounted for the 7,429 Royalty Warrants issued to the unrelated lender as a liability. We valued these warrants on the date of issuance based on a Black-Scholes option pricing model and the resulting liability is marked to market for each future period these warrants remain outstanding, with the resulting gain or loss being recorded in the statement of operations. We accounted for the 58,000 Royalty Warrants issued to the other lenders as interest expense incurred in exchange for an extension of the maturity dates of the Royalty Notes exchanged in the transaction.
	As of June 30, 2010, all of the holders of the Royalty Notes accepted common stock in repayment of their notes and agreed to the cancellation of their Royalty Warrants.
	The “Purchaser Warrants”.
	In connection with the sale of the August Note, we agreed, at maturity or early repayment of the note, to issue either common shares or warrants to purchase up to 60,000 of our common shares (the Purchaser Warrants). The Purchaser Warrants were to contain the same terms as the Convertible Note Warrants described above. Based on authoritative guidance, we accounted for the Purchaser Warrants as a liability as of the date of issuance and reduced the carrying value of the August Note by the initial fair value of these Warrants.
	On April 23, 2010, we agreed to issue to the holder of the August 2009 Note 15 million shares of our common stock in lieu of the Purchaser Warrants.
	The “Series B Warrants”
	In connection with the issuance of the Series B Preferred, we issued Series B warrants to purchase up to 75,939 shares of our common stock. The initial exercise price of the Series B Warrants was $2.50 per common share, subject to anti-dilution adjustments. The strike price of the Series B Warrants was subsequently reduced to $1.75 per common share pursuant the anti-dilution adjustment. The Series B Warrants have a 5 year term.
	The Series B Warrants provide for cashless exercise under certain circumstances. Accordingly, the amount of additional shares underlying potential future issuances of Series B Warrants is indeterminate. There is no specified cash payment obligation related to the Series B Warrants and there is no obligation to register the common shares underlying the Series B Warrants except in the event that we decide to register any of our common stock for cash (“piggyback registration rights”). Presumably, we would be obligated to make a cash payment to the holder if we failed to satisfy our obligations under these piggyback registration rights. Based on authoritative guidance, we have accounted for the Series B Warrants as liabilities. As of June 30, 2013, a total of 2,857 Series B Warrants remain outstanding, with a strike price of $0.001 per share.
	The “April 2010 Warrants”.
	In connection with the April 2010 Financing, we issued a total of 1,546,667 Class A, 1,546,667 Class B and 1,546,667 Class C Warrants (collectively, the “April 2010 Warrants”). The Class A Warrants have a 5 year term, an initial exercise price of $1.50 per common share, subject to anti-dilution adjustments and contain a “cashless exercise feature”. The Class B Warrants have a 9 month term and an initial exercise price of $1.50 per common share, subject to anti-dilution adjustments. The Class C Warrants have a 5 year and 9 month term, an initial exercise price of $1.50 per common share, subject to anti-dilution adjustments and contain a “cashless exercise feature”. The April 2010 Warrants provide the holder with “piggyback registration rights” as described above. Based on authoritative guidance, we have accounted for the April 2010 Warrants as liabilities. The liability, measured at fair value on the date of issuance using a Black-Scholes option pricing model has been offset by a reduction in the carrying value of the April 2010 Notes and will be marked to market for each future period they remain outstanding.
	On June 28, 2010, holders of 1,013,333 Class A Warrants exercised their Warrants through the cashless exercise feature and received a total of 11,000 shares of Company common stock.
	As a result of the “ratchet” provisions contained in the April 2010 Warrants, the number of warrants and the exercise price of the warrants are subject to adjustment as a result of the December 2010 Notes described above.
	On March 15, 2011 holders of 4 million Class B Warrants exercised their Warrants for cash and received a total of 4 million shares of our Common Stock. The remaining Class B Warrants expired in January 2011.
	As of October 26, 2012, a total of 53,733,333 April 2010 A warrants were exchanged for Series D Preferred shares.
	“Consultant Warrants”
	In connection with the April 2010 Financing, we issued 700,000 warrants to various consultants (the “Consultant Warrants”) with terms that are the same as those contained in the Class A Warrants. Based on authoritative guidance, we have accounted for the Consultant Warrants as liabilities.
	On June 28, 2010, holders of all of the outstanding Consultant Warrants exercised their Warrants through the cashless exercise feature and received a total of 11,000 shares of Company common stock.
	In August and October 2010, we issued an additional 6,000,000 warrants to consultants for investor relations and legal services. These warrants expire five years from the date of issuance. The exercise price of each warrant is $0.05 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans. The terms of the warrants fail to specify a penalty if we fail to satisfy our obligation under these piggyback registration rights. Presumably we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for these consultant warrants as liabilities, measured at fair value, based on a Black-Scholes option pricing model.
	As of October 26, 2012, 6,000,000 Consultant Warrants were exchanged for Series D Preferred shares.
	“The December 2010 and March 2011 Warrants”
	In connection with the sale of the December 2010 Notes and March 2011 Notes, we issued warrants, we issued a total of 20,000,000 warrants (the “December 2010 and March 2011 Warrants”). These warrants expire five years from the date of issuance. The exercise price of each warrant is $0.05 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans. The terms of the warrants fail to specify a penalty if we fail to satisfy our obligation under these piggyback registration rights. Presumably we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for these consultant warrants as liabilities, measured at fair value, based on a Black-Scholes option pricing model.
	As of October 26, 2012, 9,800,000 of December 2010 and March 2011 Warrants, were exchanged for Series D Preferred shares.
	The “June and July 2011 Warrants”
	In connection with the sale of the June Notes, we issued a total of 30 million warrants (the “June and July 2011 Warrants”). The June and July 2011 Warrants expire five years from date of issuance. The exercise price of each warrant is $0.05 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans). The terms of the June and July Warrants fail to specify a penalty if we fail to satisfy our obligations under these piggyback registration rights. Presumably, we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for the June and July 2011 Warrants as liabilities. The liability for the June and July 2011 Warrants, measured at fair value, based on a Black-Scholes option pricing model, has been offset by a reduction in the carrying value of the related Notes.
	As of October 26, 2012, 30 million “June and July 2011” warrants were exchanged for Series D Preferred shares.
	The “2011 Director Warrants”
	In October 2011, we issued warrants to purchase 2,881,680 shares of our common stock to our former independent directors in partial satisfaction of outstanding fees owed to such directors (the “2011 Director Warrants”). The 2011 Director Warrants have a 5 year term, an initial exercise price of $0.05 per common share, subject to anti-dilution adjustments, and contain a “cashless exercise feature”. The 2011 Director Warrants provide the holder with “piggyback registration rights” as described above. Based on authoritative guidance, we have accounted for the 2011 Director Warrants as liabilities. The liability, measured at fair value on the date of issuance using a Black-Scholes option pricing model will be marked to market for each future period they remain outstanding. As of June 30, 2013 2,881,680 warrants are outstanding
	The “April and May 2012” Warrants
	In connection with the sale of the April and May 2012 Notes, we issued a total of 99,150,000 warrants (the “April and May 2012 Warrants”). The April and May 2012 Warrants expire five years from date of issuance. The exercise price of each warrant is $0.05 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans). The terms of the April and May 2012 Warrants fail to specify a penalty if we fail to satisfy our obligations under these piggyback registration rights. Presumably, we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for the April and May 2012 Warrants as liabilities. The liability for the April and May 2012 Warrants, measured at fair value, based on a Black-Scholes option pricing model, has been offset by a reduction in the carrying value of the related Notes.
	As of October 26, 2012, 53,150,000 “April and May 2012” warrants were exchanged for Series D Preferred shares, while 46,000,000 warrants were outstanding as of December 31, 2012. On March 13, 2013, all of the outstanding warrants were exchanged for common stock in a cashless exercise and 29,525,879 shares of common stock were issued.
	The January 2013 Financing Warrants
	In connection with the sale of the January 2013 Notes, we issued a total of 247,500,000 warrants. The January 2013 Financing Warrants expire five years from date of issuance. The exercise price of each warrant is $0.01 per share, subject to anti-dilution adjustments. These warrants provide the holder with “piggyback registration rights”, which obligate us to register the common shares underlying the warrants in the event that we decide to register any of our common stock either for our own account or the account of a security holder (other than with respect to registration of securities covered by certain employee option plans). The terms of the January 2013 Financing Warrants fail to specify a penalty if we fail to satisfy our obligations under these piggyback registration rights. Presumably, we would be obligated to make a cash payment to the holder to compensate for such failure. Based on authoritative guidance, we have accounted for the January 2013 Financing Warrants as liabilities. The liability for the January 2013 Financing Warrants, measured at fair value, based on a Black-Scholes option pricing model, has been offset by a reduction in the carrying value of the related Notes.
	As of June 30, 2013, 247,500,000 warrants remain outstanding.

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 8. Income Taxes
	The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the years ended June 30, 2013 and 2012 to the Company’s effective tax rate is as follows:
		Years Ended
		June 30, 2013			June 30, 2012
	U.S. federal statutory rate		-34	%		-34	%
	State income tax, net of federal benefit		-6	%		-6	%
	Change in valuation allowance		40	%		40	%
	Income Tax provision (benefit)		0	%		0	%
	The tax effects of temporary differences that give rise to the Company’s net deferred tax asset as of June 30, 2013 and 2012 are as follows:
		Years Ended
		December 31, 2011			December 31, 2010
	Deferred Tax Assets
	Net operating losses	$	7,120,000		$	5,265,000
	Derivative liability		2,146,800			1,355,000
			9,266,800			6,620,000
	Less: Valuation allowance		-7,120,000			-5,265,000
			2,146,800			1,355,000
	Derivative liability		-2,146,800			-1,355,000
	Total deferred tax liability		-2,146,800			-1,355,000
	Net Deferred Tax Assets	$	-		$	-
	As of June 30, 2013, the Company had approximately $17,800,000 of Federal and state net operating loss carryovers (“NOLs”) which begin to expire in 2025. Utilization of the NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.
	In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax asset because it is more likely than not that all of the deferred tax asset will not be realized.
	The Company files U.S. federal and state of New York tax returns that are subject to audit by tax authorities beginning with the year ended June 30, 2010. The Company is not currently under audit for any tax returns

Capital_Deficiency

Capital Deficiency	12 Months Ended
	Jun. 30, 2013
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments Disclosure [Text Block]	Note 9. Capital Deficiency
	Common stock
	In April and May 2005, we issued 241,565 and 183,505 shares of common stock at $0.001 per share to founders of Intellect, yielding proceeds of $12,078 and $9,175, respectively.
	In June 2005, we issued to Goulston & Storrs, LLP a warrant to purchase 2,000 shares of our common stock at a purchase price of $0.001 per share, expiring June 20, 2008. In April 2006, Goulston & Storrs exercised the warrant and we subsequently delivered to them a share certificate representing 2,000 shares of our common stock.
	On March 10, 2006, we amended our Certificate of Incorporation to provide for the issuance of up to 2,000,000 shares of common stock and up to 15,000,000 shares of preferred stock each with a par value of $.001 per share.
	In January 2006, we issued 2,225 shares of Series A Convertible Preferred Stock, par value per share of $0.001, as partial consideration for settlement of certain claims totaling $570,000. As a result of the Merger described below, the Series A Preferred Stock was exchanged for 2,577 shares of our common stock.
	In July 2007, we issued a total of 6,595 shares of common stock to various note holders. We issued 6,230 shares as part of agreements with three note holders to extend the maturity date of their notes to September 30, 2007 and recorded a charge of $622,354 for interest expense in connection with the issuance of these shares. We issued 365 shares to three note holders who converted their notes with an aggregate principal amount and accrued interest of $31,733. On April 8, 2008, we rescinded the conversion of these notes into common shares and reinstated the Notes and agreed with the holders to cancel the shares and extend the maturity date of the notes to June 30, 2008.
	In December 2007, we issued 600 shares of common stock under a pre-existing agreement with a note holder to extend the maturity date of his note to December 15, 2007. In February 2008, we rescinded the issuance of the 600 shares of common stock and issued a note to the note holder as additional consideration for the extension.
	In December 2007, we issued 1,000 shares to a consultant for services rendered.
	On January 25, 2007, GlobePan Resources, Inc. entered into an agreement and plan of merger with Intellect and INS Acquisition, Inc., a newly formed, wholly-owned Delaware subsidiary of GlobePan Resources, Inc. also called Acquisition Sub. On January 25, 2007, Acquisition Sub merged with and into Intellect Neurosciences, Inc., Acquisition Sub ceased to exist and Intellect survived the merger and became the wholly-owned subsidiary of GlobePan Resources, Inc. GlobePan stockholders retained, in the aggregate, 180,000 shares of their common stock.
	In November 2009, we amended our Certificate of Incorporation to provide for the issuance of up to 13,000,000 shares of common stock with a par value of $.001 per share.
	In April 2010, we amended our Certificate of Incorporation to provide for the issuance of up to 40,000,000 shares of common stock with a par value of $.001 per share.
	In April 2010, we issued 4,261,194 shares of our Common stock as full repayment of principal and interest owed to holders of Convertible Promissory Notes. All of these Notes were in default.
	In April 2010, we issued 2,865,374 shares of our Common stock as full repayment of principal and interest owed to holders of Senior Promissory Notes.
	In April, 2010, we issued 4,138,935 shares of our Common stock to holders of Series B Preferred Stock upon their exercise of the conversion feature contained in those securities.
	As described above, in connection with the sale of the November Notes, we agreed that the purchasers of the November Notes will receive at maturity of the November Notes 50,000 shares of our common stock. Simultaneous with the issuance of the November Notes, Daniel Chain, our CEO, transferred to an escrow agent, 50,000 shares of Company common stock issued to him at the time that he founded the Company in 2005 as collateral for the purchasers’ right to receive such shares. On April 23, 2010, the holders of the November Notes accepted common stock in repayment of their notes in conjunction with the financing transaction described above and the escrow agent released the Purchaser Shares to the holders of the November Notes. In April 2010, we issued 50,000 shares to Dr. Chain to replace the shares that he had surrendered to the holders of the November Notes.
	On April 23, 2010, we sold 1,160,000 shares of our common stock for aggregate consideration of $1,740,000 as part of the sale of investment units.
	In April 2010, we issued 1,327,583 shares of our common stock to various consultants.
	In April 2010, we issued 77,403 shares of our common stock to a former holder of our Convertible Promissory Notes in settlement of a claim.
	In April 2010, we issued 21,000 shares of our common stock to certain of our trade creditors in partial settlement of past due amounts owed to these creditors.
	In June 2010, we issued 1,765,240 shares of our common stock to holders of Class A Warrants and Consultant Warrants upon the cashless exercise of those warrants.
	In July 2010, we repaid outstanding 2007 Notes through the issuance of 262,338 shares of our common stock and the holder agreed to the cancellation of the associated warrants.
	In August 2010, we issued 10,000 shares of our common stock to our sole independent director as and 70,000 shares of our common stock to various consultants.
	In November and December 2010, we issued 3,826,000 shares of our common stock to holders of $237,500 of April 2010 Notes upon conversion of their Notes.
	On December 28, 2010, we issued 800,000 shares of our common stock to a holder of Series B Preferred upon conversion of his shares.
	On January 4, 2011, we issued 362,358 shares of our common stock to holders of April 2010 Notes upon conversion of their Notes (plus accrued interest).
	On January 12, 2011, we issued 1,000,000 shares of our common stock to a holder of Series B Preferred upon conversion of his shares and 800,000 shares of our common stock to holders of April 2010 Notes upon conversion of their Notes (plus accrued interest).
	On January 20, 2011, we issued 694,417 shares of our common stock to holders of April 2010 Notes upon conversion of their Notes (plus accrued interest).
	On February 15, 2011, we issued one million shares of our common stock to a holder of Series B Preferred upon conversion of his shares.
	On March 9, 2011, we issued 1,500,000 shares of our common stock to a holder of Series B Preferred upon conversion of his shares.
	On March 10, 2011, we issued 1,200,000 shares of our common stock to a holder of Series B Preferred upon conversion of his shares.
	On March 14, 2011, we issued 2 million shares of our common stock to holders of the April 2010 Warrants upon the cashless exercise of those warrants.
	On March 17, 2011, we issued 13,750 shares of our common stock to a consultant in exchange for public relations consulting services performed during 2011.
	On March 17, 2011, we issued 3,714,286 shares of our common stock to holders of the December 2010 Warrants upon the cashless exercise of those warrants.
	During the year ended June 30, 2012 we had the following capital transactions:
	In July 2011, we issued 5,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In September 2011, we issued 1,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In October 2011, we issued 2,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In October 2011, we issued warrants to purchase 2,881,680 shares of our common stock at an exercise price of $0.05 per share to our former independent directors in partial satisfaction of outstanding fees owed to such directors.
	In December 2011, we issued 3,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In January 2012 we issued 545,000 shares of common stock to a vendor in satisfaction of outstanding fees owed to the vendor.
	In February 2012, we issued 5,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In February 2012, we issued 1,515,306 shares of common stock to holders of our April 2010 Warrants upon their exercise of the cashless exercise feature contained in those securities.
	In March 2012, we issued 2,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In March 2012, we issued 1,928,571 shares of common stock to holders of our April 2010 Warrants upon their exercise of the cashless exercise feature contained in those securities.
	In April 2012, we issued 4,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In April 2012, we issued 2,500,000 shares of our common stock in consideration for services rendered to the Company.
	In May 2012, we issued 500,000 shares of our common stock for the conversion of a portion of the principal amount of a Convertible Promissory Note.
	In May 2012, we issued 2,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In June 2012, we issued 2,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In June 2012, we issued 500,000 shares of our common stock in consideration for services rendered to the Company.
	In July 2012, we issued 2,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In August 2012, we issued 1,000,000 shares of our common stock in consideration for services rendered to the Company.
	In September 2012, we issued 1,750,000 shares of our common stock in consideration for services rendered to the Company.
	In September 2012, we issued 3,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In January 2013, we issued 5,000,000 shares of our common stock in consideration for services rendered to the Company.
	In January 2013, we issued 2,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In February 2013, we issued 20,000,000 shares of our common stock to holders of Series D Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In February 2013, we issued 8,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In March 2013, we issued 8,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In March 2013, we issued 29,525,879 shares of our common stock to holders of 46,000,000 warrants upon their cashless exercise of the conversion feature contained in those securities.
	In April 2013, we issued 14,000,000 shares of our common stock to holders of Series C Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.
	In May 2013, we issued 9,500,000 shares of our common stock in consideration for services rendered to the Company.
	In May 2013, we issued 5,000,000 shares of our common stock to holders of Series D Convertible Preferred Stock upon their exercise of the conversion feature contained in those securities.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2013
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 10. Related Party Transactions
	University of South Florida Agreement. Our AD research activities require that we test our drug candidates in a certain type of transgenic mouse that exhibits the human AD pathology. Mindgenix, Inc., a wholly-owned subsidiary of Mindset, holds a license on the proprietary intellectual property related to these particular mice from the University of South Florida Research Foundation (“USFRF”). We have engaged Mindgenix to perform testing services for us using these transgenic mice. Dr. Chain, our CEO, is a controlling shareholder of Mindset. We consolidate the results of operations of Mindgenix with our results of operations because we have agreed to absorb certain costs and expenses incurred that are attributable to their research.
	In December of 2006, we entered into an agreement with USFRF as a co-obligor with Mindgenix, pursuant to which USFRF agreed to reinstate the license with Mindgenix in exchange for our agreement to pay to USFRF $209,148 plus accrued interest of $50,870. This amount is in settlement of a previously outstanding promissory note issued by Mindgenix to the USFRF dated September 30, 2004. Our obligation to pay amounts due under the agreement are as follows: $109,148 was payable on January 15, 2007 and $100,000 is payable in six equal monthly installments of $16,667 beginning February 1, 2007 and ending with a final payment of $50,435 on August 1, 2007. We have paid $184,151 through June 30, 2009. We have recorded these amounts as research and development expense and established a liability for the remainder of the payments. In addition, we have incurred approximately $325,000 in operating costs on behalf of Mindgenix for the fiscal year ended June 30, 2009. These amounts have been included in our consolidated results of operations as research and development expense.
	In April 2008, we paid $100,000 on behalf of Mindgenix and Mindgenix issued a promissory note with a face amount of $100,000 to Harlan Biotech, Israel, an unrelated third party (‘the “Harlan Note”), as partial payment for past due fees related to maintenance of Mindgenix’ mouse colony. The Harlan Note bears interest at 10% per annum and is due 40 days from the issue date of April 8, 2008. One of our principal shareholders posted with an escrow agent 4,300 shares of freely tradable Intellect common stock as security for the Harlan Note. The shares were sold for total consideration of $104,244 and the proceeds were remitted to Harlan in discharge of the Harlan Note. We issued a convertible promissory note to the shareholder with a face amount of $104,244 and recorded a corresponding research and development expense.
	Consulting Contracts. We have entered into consulting contracts with various members of our Clinical and Scientific Advisory Boards. Certain of these individuals are shareholders of Intellect. The consulting contracts are for services to be rendered in connection with ongoing research and development of our drug candidates. The contracts generally provide for per-diem payments of $2,500 for days spent away from the office attending to Intellect affairs.

Commitments_and_Contingencies

Commitments and Contingencies.	12 Months Ended
	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 11. Commitments and Contingencies.
	In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our product candidates, use of such product candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of June 30, 2013 and 2012.
	In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the action of various regulatory agencies. If necessary, management consults with counsel and other appropriate experts to assess any matters that arise. If, in management’s opinion, we have incurred a probable loss as set forth by accounting principles generally accepted in the United States, an estimate is made of the loss, and the appropriate accounting entries are reflected in our financial statements. We do not anticipate that liabilities arising out of currently pending or threatened lawsuits and claims will have a material adverse effect on our financial position, results of operations or cash flows.

StockBased_Compensation_Plans

Stock-Based Compensation Plans-	12 Months Ended
	Jun. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 12. Stock-Based Compensation Plans-
	In December 2006, our stockholders approved the adoption of the "2006 Employee, Director and Consultant Stock Plan" (the "2006 Stock Plan"), under which 240,000 shares of our common stock are available for issuance under the Plan. The 2006 Stock Plan provides for the grant of either ISOs or non-qualified stock options, which do not qualify as ISOs.
	On January 25, 2007, we granted 139,905 stock options to our Chairman and CEO and 60,838 stock options to our Chief Financial Officer. The option exercise price is $37.00 per share. The options are fully vested.
	On March 30, 2009, we granted 500 stock options to a consultant engaged by the Company to assist in research and development activities related to OX1. The grant was effective as of that date with a strike price of $17.50. The stock options vest over a twelve month period and are exercisable through March 30, 2014.
	On August 31, 2010, we granted 2,000 stock options to a consultant engaged by the Company to assist in research and development activities. The grant was effective as of that date with a strike price of $0.83. The stock options vest over a twelve month period and are exercisable through August 31, 2015.
	On June 13, 2011, we granted 10,000 stock options to a consultant engaged by the Company to assist in research and development activities. The grant was effective as of that date with a strike price of $0.10. The stock options vest over a twelve month period and are exercisable through June 13, 2016.
	The exercise price of all the above stock options was the closing price of the stock on the day of the grant.
	As of June 30, 2013 and 2012, there are 26,757 stock options available for grant under the 2006 Stock Plan, respectively.
	A summary of our outstanding stock options under all plans at June 30, 2013 is as follows:
		Year Ended		Weighted		Instrinisic		Weighted
		June 30, 2013		Average		value		Average
				Exercise Price				Remaining
								Contractual
								Life
	Options outstanding at June 30, 2012		213,243	$	34.87	$	-		3.35
	Granted		-	$	-				-
	Cancelled/Forfeited		-	$	-		-
	Expired		-	$	-
	Balance at the end of period		213,243	$	34.87		-		3.35
	Options excercisable at June 30, 2013		213,243	$	34.87		-		3.35
	Options vested or expected to vest		213,243	$	34.87		-		3.35
	Total compensation expense recorded during the year ended June 30, 2013 and 2012 for share-based payment awards was $0, and $256 respectively, which is recorded in general and administrative expenses in the consolidated statement of operations.

Per_Share_Data

Per Share Data	12 Months Ended
	Jun. 30, 2013
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 13. Per Share Data
	The following table sets forth the information needed to compute basic and diluted earnings per share:
			Twelve Months Ended
			June 30		June 30
			2013		2012
	Basic EPS
	Net income (loss) attributable to common stockholders, basic		$	-9,755,510	$	1,896,990
	Weighted average shares outstanding			136,468,981		81,002,258
	Basic income earnings per share		$	-0.07	$	0.02
	Diluted EPS
	Net income (loss) attributable to common stockholders, basic		$	-9,755,510	$	1,896,990
	Preferred stock dividends			2,592,550		2,278,171
	Interest on convertible notes			290,005		192,293
	Net income (loss) attributable to common stockholders, diluted		$	-6,872,955	$	4,367,454
	Weighted average shares outstanding			136,468,981		81,002,258
	Dilutive effect of stock options			-		-
	Dilutive effect of warrants			104,552,263		99,683,882
	Dilutive effect of Series B preferred shares			4,593,090		4,593,090
	Dilutive effect of Series C preferred shares			404,340,000		427,810,959
	Dilutive effect of convertible notes			163,181,250		34,580,000
	Diluted weighted average shares outstanding (A)			813,135,584		647,670,189
	(A)	For the year ended June 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Subsequent_Events

Subsequent Events	12 Months Ended
	Jun. 30, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 14. Subsequent Events
	In accordance with authoritative guidance, we have evaluated any events or transactions occurring after June 30, 2013, the balance sheet date, through the date of filing of this report and note that there have been no such events or transactions that would require recognition or disclosure in the consolidated financial statements as of and for the year ended June 30, 2013, except as disclosed below.
	a) During July, 2013, we sold investment units for an aggregate purchase price of $92,500. Each unit consisted of a Convertible Promissory Note and warrants under the same terms as the January 2013 Financing. Total proceeds from the sale of these investment units were $92,500.
	b) On August 5, 2013 we issued 15,000,000 shares of the Company’s common stock to a consultant for services rendered for the Company.
	c) On August 7, 2013, a holder of the Company’s Series C Convertible Preferred Stock converted $675,000 Stated Value of such Preferred Stock, at a conversion price of $0.05 per share, into 13,500,000 shares of the Company’s common stock.
	d) During August, 2013, we sold investment units for an aggregate purchase price of $150,000. Each unit consisted of a Convertible Promissory Note and warrants under the same terms as the January 2013 Financing. Total proceeds from the sale of these investment units were $150,000.
	e) On September 10, 2013, a holder of the Company’s Series C Convertible Preferred Stock converted $350,000 Stated Value of such Preferred Stock, at a conversion price of $0.05 per share, into 7,000,000 shares of the Company’s common stock.
	f) On September 16, 2013, a holder of the Company’s Series D Convertible Preferred Stock converted $825,000 Stated Value of such Preferred Stock, at a conversion price of $0.05 per share, into 16,500,000 shares of the Company’s common stock.
	g) During September, 2013, we sold investment units for an aggregate purchase price of $25,000. Each unit consisted of a Convertible Promissory Note and warrants under the same terms as the January 2013 Financing. Total proceeds from the sale of these investment units were $150,000.
	h) On October 9, 2013 we issued 19,500,000 shares of the Company’s common stock to a consultant for services rendered for the Company.
	i) On October 9, 2013, a holder of the Company’s Series D Convertible Preferred Stock converted $265,111 Stated Value of such Preferred Stock, at a conversion price of $0.05 per share, into 5,302,222 shares of the Company’s common stock.
	j) During October, 2013, we sold investment units for an aggregate purchase price of $75,000. Each unit consisted of a Convertible Promissory Note and warrants under the same terms as the January 2013 Financing. Total proceeds from the sale of these investment units were $75,000.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation. The consolidated financial statements include the accounts of our wholly owned subsidiary, Intellect Israel, and the accounts of Mindgenix, Inc. (“Mindgenix”), a wholly-owned subsidiary of Mindset Biopharmaceuticals, Inc. (“Mindset”). We consolidate Mindgenix because we have agreed to absorb certain costs and expenses incurred by Mindgenix that are attributable to its research. Dr. Chain, our CEO, is a controlling shareholder of Mindset and the President of Mindgenix. All inter-company transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates. The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates include the fair value of derivative instruments, including stock options and warrants to purchase our common stock, recognition of clinical trial costs, certain consulting expenses and deferred taxes. Actual results may differ substantially from these estimates.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation. We recognize compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, we calculate the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, we calculate the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs and Clinical Trial Expenses. Research and development costs include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses, the full cost of manufacturing drugs for use in research, preclinical development, and clinical trials. All costs associated with research and development are expensed as incurred.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition. We recognize revenue in accordance with authoritative accounting guidance, which provides that non-refundable upfront and research and development milestone payments and payments for services are recognized as revenue as the related services are performed over the term of the collaboration.
Debt, Policy [Policy Text Block]	Convertible Instruments We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.
	We account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. We also record when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
Common Stock Purchase Warrants [Policy Text Block]	Common Stock Purchase Warrants We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess classification of our common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	Preferred Stock. We apply the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity” when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders’ equity.
Derivatives, Policy [Policy Text Block]	Derivative Instruments. Our derivative financial instruments consist of embedded derivatives related to the convertible debt, warrants and beneficial conversion features embedded within our convertible debt. The accounting treatment of derivative financial instruments requires that we record the derivatives and related warrants at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each balance sheet date. If the fair value of the derivatives was higher at the subsequent balance sheet date, we recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, we recorded non-operating, non-cash income.
	During the years ended June 30, 2013 and 2012, we recognized other income of approximately $2.5 million and $7.2 million, respectively, relating to recording the derivative liabilities at fair value. At June 30, 2013 and 2012 there were approximately $2.6 million and $3.4 million of derivative liabilities.
	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the year ended June 30, 2013:
	Estimated dividends	None
	Expected volatility	331%
	Risk-free interest rate	1.45%
	Expected term (years)	1.0 - 5.0 years
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments. We adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.
	The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.
	ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	We measure derivative liabilities at fair value using the Black-Scholes option pricing model with assumptions that include the fair value of the stock underlying the derivative instrument, the exercise or conversion price of the derivative instrument, the risk free interest rate for a term comparable to the term of the derivative instrument and the volatility rate and dividend yield for our common stock. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has not paid dividends to date and does not expect to pay dividends in the foreseeable future due to its substantial accumulated deficit. Accordingly, expected dividends yields are currently zero. Expected volatility is based principally on an analysis of historical volatilities of similarly situated companies in the marketplace for a number of periods that is at least equal to the contractual term or estimated life of the applicable financial instrument.
	We also considered the use of the lattice or binomial models with respect to valuing derivative financial instruments that feature anti-dilution price protection; however, the differences in the results are insignificant due to the low probability of triggering price adjustments in such financial instruments.
Income Tax, Policy [Policy Text Block]	Income taxes. We use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.
	ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share. Basic net income or basic net loss per common share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options, convertible debt, and convertible preferred stock are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Pronouncements
	In May 2011, the FASB issued ASU 2011-04, “Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS” (“ASU 2011-04”). The amendments in ASU 2011-04 result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, ASU 2011-04 changes the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, the FASB does not intend for the amendments in ASU 2011-04 to result in a change in the application of the requirements in Topic 820. ASU 2011-04 is effective prospectively for interim and annual reporting periods beginning after December 15, 2011. This ASU will become effective for the company beginning in the quarter ended January 31, 2012 and we do not expect an impact on our consolidated financial statements
	In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. The guidance in ASU 2011-05 applies to both annual and interim financial statements and eliminates the option for reporting entities to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. This ASU also requires consecutive presentation of the statement of net income and other comprehensive income. Finally, this ASU requires an entity to present reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this ASU should be applied retrospectively and are effective for fiscal year, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial position or results of operations.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]
Schedule of Derivative Instruments [Table Text Block]	Our derivative instruments were valued using the Black-Scholes option pricing model, using the following assumptions during the year ended June 30, 2013:
	Estimated dividends	None
	Expected volatility	331%
	Risk-free interest rate	1.45%
	Expected term (years)	1.0 - 5.0 years

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2013
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses consist of the following:
		June 30, 2013		June 30, 2012
	Professional Fees	$	1,080,675	$	1,160,080
	Consulting Expenses		853,197		733,197
	Clinical Expenses		206,890		766,890
	Other		346,648		289,597
	Total	$	2,487,410	$	2,949,764

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Jun. 30, 2013
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The following table sets forth a summary of all of the outstanding convertible promissory notes at June 30, 2013:
	Convertible promissory notes issued	$	3,657,500
	Allocated to preferred stock		-256,203
	Notes repaid		-400,000
	Less amounts converted to common stock		-625,000
			2,376,297
	Less debt discount		1,144,560
	Balance June 30, 2013	$	1,231,737

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the years ended June 30, 2013 and 2012 to the Company’s effective tax rate is as follows:
		Years Ended
		June 30, 2013			June 30, 2012
	U.S. federal statutory rate		-34	%		-34	%
	State income tax, net of federal benefit		-6	%		-6	%
	Change in valuation allowance		40	%		40	%
	Income Tax provision (benefit)		0	%		0	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The tax effects of temporary differences that give rise to the Company’s net deferred tax asset as of June 30, 2013 and 2012 are as follows:
		Years Ended
		December 31, 2011			December 31, 2010
	Deferred Tax Assets
	Net operating losses	$	7,120,000		$	5,265,000
	Derivative liability		2,146,800			1,355,000
			9,266,800			6,620,000
	Less: Valuation allowance		-7,120,000			-5,265,000
			2,146,800			1,355,000
	Derivative liability		-2,146,800			-1,355,000
	Total deferred tax liability		-2,146,800			-1,355,000
	Net Deferred Tax Assets	$	-		$	-

StockBased_Compensation_Plans_

Stock-Based Compensation Plans- (Tables)	12 Months Ended
	Jun. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of our outstanding stock options under all plans at June 30, 2013 is as follows:
		Year Ended		Weighted		Instrinisic		Weighted
		June 30, 2013		Average		value		Average
				Exercise Price				Remaining
								Contractual
								Life
	Options outstanding at June 30, 2012		213,243	$	34.87	$	-		3.35
	Granted		-	$	-				-
	Cancelled/Forfeited		-	$	-		-
	Expired		-	$	-
	Balance at the end of period		213,243	$	34.87		-		3.35
	Options excercisable at June 30, 2013		213,243	$	34.87		-		3.35
	Options vested or expected to vest		213,243	$	34.87		-		3.35

Per_Share_Data_Tables

Per Share Data (Tables)	12 Months Ended
	Jun. 30, 2013
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the information needed to compute basic and diluted earnings per share:
			Twelve Months Ended
			June 30		June 30
			2013		2012
	Basic EPS
	Net income (loss) attributable to common stockholders, basic		$	-9,755,510	$	1,896,990
	Weighted average shares outstanding			136,468,981		81,002,258
	Basic income earnings per share		$	-0.07	$	0.02
	Diluted EPS
	Net income (loss) attributable to common stockholders, basic		$	-9,755,510	$	1,896,990
	Preferred stock dividends			2,592,550		2,278,171
	Interest on convertible notes			290,005		192,293
	Net income (loss) attributable to common stockholders, diluted		$	-6,872,955	$	4,367,454
	Weighted average shares outstanding			136,468,981		81,002,258
	Dilutive effect of stock options			-		-
	Dilutive effect of warrants			104,552,263		99,683,882
	Dilutive effect of Series B preferred shares			4,593,090		4,593,090
	Dilutive effect of Series C preferred shares			404,340,000		427,810,959
	Dilutive effect of convertible notes			163,181,250		34,580,000
	Diluted weighted average shares outstanding (A)			813,135,584		647,670,189
	(A)	For the year ended June 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Business_Description_and_Going1

Business Description and Going Concern (Details Textual) (USD $)	1 Months Ended	12 Months Ended		98 Months Ended
	Apr. 30, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2009	Jun. 30, 2008	Jun. 30, 2007	Jun. 30, 2006	Jun. 30, 2005
License fees		$0	$6,500,000	$10,516,667
Cash and cash equivalents		5,138	2,307	5,138	101,325
Stockholders' Equity, Reverse Stock Split	50 to1
Working Capital Deficit		12,321,404		12,321,404
Development Stage Enterprise, Deficit Accumulated During Development Stage		83,891,966	74,136,456	83,891,966
Operating Income (Loss)		-4,347,686	283,782	-49,493,607
Net Cash Provided By (Used In) Operating Activities		-1,130,669	-83,018	-22,019,932
Stockholders' Equity Attributable To Parent		($13,548,426)	($11,079,928)	($13,548,426)	($13,363,074)	($20,312,120)	($19,656,864)	($21,974,434)	($43,196,621)	($3,475,019)	($759,034)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2013
Estimated dividends	None
Expected volatility	331.00%
Risk-free interest rate	1.45%
Minimum [Member]
Expected term (years)	1 year
Maximum [Member]
Expected term (years)	5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended		1 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012	31-May-11	Jun. 30, 2011
			Accounting Standards Update 2011-04 [Member]	Accounting Standards Update 2011-05 [Member]
Derivative, Gain (Loss) on Derivative, Net, Total	$2.50	$7.20
Derivative Liabilities	$2.60	$3.40
New Accounting Pronouncement or Change in Accounting Principle, Description			In May 2011, the FASB issued ASU 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS (ASU 2011-04). The amendments in ASU 2011-04 result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, ASU 2011-04 changes the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, the FASB does not intend for the amendments in ASU 2011-04 to result in a change in the application of the requirements in Topic 820. ASU 2011-04 is effective prospectively for interim and annual reporting periods beginning after December 15, 2011. This ASU will become effective for the company beginning in the quarter ended January 31, 2012 and we do not expect an impact on our consolidated financial statements	In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. The guidance in ASU 2011-05 applies to both annual and interim financial statements and eliminates the option for reporting entities to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. This ASU also requires consecutive presentation of the statement of net income and other comprehensive income. Finally, this ASU requires an entity to present reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this ASU should be applied retrospectively and are effective for fiscal year, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Companys financial position or results of operations.

Material_Agreements_Details_Te

Material Agreements (Details Textual) (USD $)

12 Months Ended

98 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2005

Sep. 30, 2011

Jun. 30, 2005

Sep. 30, 2012

Sep. 30, 2011

Jun. 30, 2000

Jun. 30, 2013

Sep. 16, 2012

Jun. 30, 2013

Aug. 31, 2008

31-May-08

Dec. 31, 2008

Oct. 31, 2008

Apr. 30, 2009

Jun. 30, 2013

Research and License Agreements [Member]

Research and License Agreements [Member]

Viropharma License Agreements [Member]

Viropharma License Agreements [Member]

Chimeric Peptide Assignment Agreement [Member]

Beta Amyloid Purchase and Sale Agreement [Member]

Research Collaboration Agreement [Member]

Research Collaboration Agreement [Member]

Elan and Wyeth License Agreement [Member]

Elan and Wyeth License Agreement [Member]

Antisenilin Option and License Agreement [Member]

Antisenilin Option and License Agreement [Member]

Gsk Option and License Agreement [Member]

Northwestern University License Agreement [Member]

Future Payments For Clinical Development

$3,000,000

$700,000

Licenses Revenue

0

6,500,000

10,516,667

6,500,000

6,500,000

1,000,000

1,000,000

License Fee Payment

650,000

200,000

Royalty Payment Related Party Percentage

1.50%

Payments For Clinical Development

2,125,000

560,000

Warrants Issued Payments For Clinical Development

560,000

Clinical Development Payments Outstanding

350,000

Issuance Of Warrants

11,200,000

Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights

0.001

0.0625

Research Expenses Abandonment

50,000

Non Refundable Fee

500,000

Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options

1,550,000

2,000,000

2,000,000

Additional Grant Received Licensed Patent

$2,000,000

$2,000,000

Revenue Recognition, Milestone Method, Milestone

$120 million

License Agreement Termination Description

at any time upon ninety (90) days prior written notice to the Company

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Professional Fees	$1,080,675	$1,160,080
Consulting Expenses	853,197	733,197
Clinical Expenses	206,890	766,890
Other	346,648	289,597
Total	$2,487,410	$2,949,764

Notes_Payable_Details

Notes Payable (Details) (USD $)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Convertible promissory notes issued	$3,657,500
Allocated to preferred stock	-256,203
Notes repaid	-400,000
Less amounts converted to common stock	-625,000
Long-term Debt, Gross	2,376,297
Less debt discount	1,144,560
Balance June 30, 2013	$1,231,737	$442,155

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)	Jun. 30, 2005	Nov. 30, 2010	Apr. 30, 2010	Nov. 03, 2010	Apr. 23, 2010	31-May-11	Jan. 31, 2011	Dec. 31, 2010	Jun. 30, 2013	Jun. 30, 2011	Dec. 15, 2010	Dec. 31, 2010	Dec. 15, 2010	Dec. 15, 2010	Jun. 30, 2013	Dec. 15, 2010	31-May-11	Jun. 30, 2013	Jun. 30, 2011	Mar. 15, 2011	Mar. 15, 2011	Jun. 30, 2013	Mar. 15, 2011	Jun. 30, 2011	Jun. 30, 2011	Apr. 30, 2012	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013
		Convertible Promissory Notes April 2010 [Member]	Convertible Promissory Notes April 2010 [Member]	Convertible Promissory Notes April 2010 [Member]	Convertible Promissory Notes April 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes December 2010 [Member]	Convertible Promissory Notes March 2011 [Member]	Convertible Promissory Notes March 2011 [Member]	Convertible Promissory Notes March 2011 [Member]	Convertible Promissory Notes March 2011 [Member]	Convertible Promissory Notes March 2011 [Member]	Convertible Promissory Notes March 2011 [Member]	Convertible Promissory Notes March 2011 [Member]	Convertible Promissory Notes June 2011 [Member]	Convertible Promissory Notes June 2011 [Member]	Convertible Promissory Notes July 2011 [Member]	Convertible Promissory Notes July 2011 [Member]	Convertible Promissory Notes July 2011 [Member]	Convertible Promissory Notes April and May 2012 [Member]	Convertible Promissory Notes April and May 2012 [Member]	Convertible Promissory Notes April and May 2012 [Member]	Convertible Promissory Notes July August and September 2012 [Member]	Convertible Promissory Notes January 2013 [Member]	Convertible Promissory Notes January 2013 [Member]
												Convertible Series C Preferred Stock [Member]	Convertible Series C Preferred Stock [Member]	Common Stock [Member]	Warrant [Member]	Warrant [Member]					Convertible Series C Preferred Stock [Member]	Warrant [Member]	Warrant [Member]		Warrant [Member]			Warrant [Member]		Convertible Series C Preferred Stock [Member]	Warrant [Member]			Warrant [Member]
Debt Instrument, Face Amount				$150,000	$580,000						$500,000									$500,000				$100,000			$150,000		$201,500				$503,500
Debt Instrument, Interest Rate During Period			14.00%						14.00%									14.00%						14.00%			14.00%		14.00%				14.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value			41,093,377																						817,151			1,626,973			1,100,650			2,400,728
Proceeds from Issuance of Debt		150,000
Debt Instrument Convertible Conversion Price Original				$1.50
Debt Instrument Convertible Conversion Price Reduced				$0.13
Face Amount Of Investment Units Sold											500,000									500,000				100,000			150,000		201,500			662,500	372,500
Proceeds From Investment Units Sold								500,000									500,000	500,000						100,000			150,000		201,500			662,500	503,500
Debt Instrument, Convertible, Conversion Price											$0.13									$0.13			$0.13	$0.05			$0.05		$0.05				$0.01
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.001			0.125							0.125													0.05			0.05		0.05				0.01
Common Stock, Capital Shares Reserved for Future Issuance											10,000					4,000,000				10,000,000	200,000,000		4,000,000	10,000,000
Share Price														$0.00
Preferred stock, liquidated (in dollars)													10,000,000								10,000,000
Stock Issued During Period, Value, New Issues												10,000,000															20,000,000			25,150,000			247,500,000
Number Of Common Stock Shares To Be Issued Upon Conversion Of Series C Preferred Shares											200,000,000										10,000
Price Of Common Stock Shares To Be Issued Upon Conversion Of Series C Preferred Shares											$0.05									$0.00	$0.00
Proceeds From Investment Units Sold Allocated To Notes Payable									25,000									25,000
Proceeds From Investment Units Sold Allocated To Series C Preferred Stock									475,000									475,000
Interest Expense, Debt									353,017						378,017			353,017				378,017		717,151			1,476,973				899,150		2,028,228
Debt Instrument, Convertible, Beneficial Conversion Feature										475,000									475,000
Revised Price Of Common Stock Shares To Be Issued Upon Conversion Of Series B Preferred Shares							$0.00
Additional Series C Preferred Stock Shares Issued As Per Ratchet Provisions							2,000
Liquidation Preference Value Of Additional Series C Preferred Stock Shares Issued As Per Ratchet Provisions							2,000,000
Additional Number Of Common Stock Shares To Be Issued Upon Conversion Of Series C Preferred Shares As Per Ratchet Provisions							40,000,000
Price Of Additional Common Stock Shares To Be Issued Upon Conversion Of Series C Preferred Shares As Per Ratchet Provisions							$0.00
Additional Common Stock Shares Issued As Per Ratchet Provisions						429,000
Decrease In Fair Value Of Notes																								100,000			150,000		201,500				503,500
Debt Conversion, Converted Instrument, Shares Issued																										500,000
Debt Conversion, Converted Instrument, Amount																										$25,000

Series_B_Convertible_Preferred1

Series B Convertible Preferred Stock and Derivative Liability (Details Textual) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

Jun. 30, 2013

Jun. 30, 2007

Jun. 30, 2012

Mar. 10, 2011

Mar. 09, 2011

Jan. 12, 2011

Dec. 28, 2008

Dec. 15, 2010

Jun. 30, 2013

Apr. 30, 2013

Mar. 31, 2013

Jul. 31, 2012

Jun. 30, 2012

31-May-12

Apr. 30, 2012

Mar. 31, 2012

Feb. 29, 2012

Dec. 31, 2011

Oct. 31, 2011

Sep. 30, 2011

Jul. 31, 2011

Oct. 31, 2010

Jun. 30, 2013

Oct. 24, 2010

Jan. 31, 2013

Jan. 02, 2013

Jun. 30, 2013

Jun. 30, 2013

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Shares [Member]

Series D Convertible Preferred Shares [Member]

Series D Convertible Preferred Shares [Member]

Series E Convertible Preferred Shares [Member]

Series E Convertible Preferred Shares [Member]

December 2010 Notes [Member]

March 2011 Notes [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Stock Issued During Period, Value, New Issues

459,309

10,000

Preferred Stock, Dividend Rate, Percentage

6.00%

Preferred Stock Initial Conversion Price Per Share

$1.75

$0.05

$0.05

$0.01

Convertible Preferred Stock, Total Shares Issued Upon Conversion

10

1,200,000

1,500,000

1,000,000

800,000

37,000,000

14,000,000

8,000,000

2,000,000

2,000,000

2,000,000

4,000,000

2,000,000

5,000,000

3,000,000

2,000,000

1,000,000

5,000,000

25,000,000

134,320,000

200,000,000

240,000,000

200,000,000

Issuance Of Warrants

3,046,756

Preferred Stock Stated Value Per Share

$17.50

$1,000

$1,000

$1,000

Preferred stock, liquidated (in dollars)

$1,870,380

$1,870,380

$19,790,000

$20,700,000

Preferred Stock Fair Value

172,874

500,000

Preferred Stock Aggregate Liquidation Preference Value

12,000,000

10,000,000

Convertible Preferred Stock Shares Issued

6,716

2,000

12,000

Dividends Payable

576,934

700,000

Reduced Conversion Price Per Share

$0.05

Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature

$700,000

Outstanding_Warrants_and_Warra1

Outstanding Warrants and Warrant Liability (Details Textual) (USD $)

Jun. 30, 2013

Dec. 31, 2012

Jun. 30, 2012

Jun. 30, 2005

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2009

Jun. 30, 2008

Jun. 30, 2007

Jun. 30, 2013

Jun. 30, 2013

Apr. 23, 2010

Feb. 29, 2012

Jun. 30, 2013

Oct. 26, 2012

Jun. 28, 2010

Jan. 28, 2010

Mar. 31, 2011

Jun. 30, 2013

Mar. 15, 2011

Jun. 30, 2013

Apr. 30, 2010

Jun. 30, 2013

Oct. 26, 2012

Jun. 28, 2010

Jun. 30, 2013

Oct. 26, 2012

Jun. 30, 2013

Oct. 31, 2011

Jun. 30, 2013

Jun. 30, 2013

Oct. 26, 2012

Mar. 13, 2013

Jun. 30, 2013

Series B Warrants [Member]

Warrants 2006 [Member]

Convertible Note Warrants [Member]

Convertible Note Warrants [Member]

Convertible Note Warrants [Member]

Convertible Note Warrants [Member]

Royalty Warrants [Member]

Purchaser Warrants [Member]

Purchaser Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

Consultant Warrants [Member]

Consultant Warrants [Member]

Consultant Warrants [Member]

Consultant Warrants [Member]

December 2010 and March 2011 Warrants [Member]

December 2010 and March 2011 Warrants [Member]

June and July 2011 Warrants [Member]

Director Warrants 2011 [Member]

Director Warrants 2011 [Member]

April and May 2012 Warrants [Member]

April and May 2012 Warrants [Member]

April and May 2011 [Member]

January 2013 Warrants [Member]

Class A Warrants [Member]

Class A Warrants [Member]

Class A Warrants [Member]

Class A Warrants [Member]

Class B Warrants [Member]

Class B Warrants [Member]

Class B Warrants [Member]

Class C Warrants [Member]

Issuance Of Warrants

75,939

43,428

7,429

3,714

76,751

65,429

60,000

1,546,667

1,546,667

1,546,667

20,000,000

30,000,000

99,150,000

247,500,000

Warrants Expiration, Term

5 years

0 years

5 years

9 months

5 years 9 months

0 years

5 years

5 years

5 years

0 years

Remaining Warrants Expiration Description

except for 22,857 of such warrants, which expire in 2013

Warrants Exercise Price, Calculated Percentage

50.00%

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.001

0.001

0.05

0.05

0.05

0.05

0.05

0.05

0.05

0.01

Shares Underlying Warrant Description

The number of shares underlying each 2006 Warrant is the quotient of the face amount of the related 2006 Note divided by 50% of the price per equity security issued in the Next Equity Financing, which occurred on May 12, 2006

Class of Warrant or Right, Outstanding

46,000,000

2,857

2,881,680

247,500,000

Exercise Price Of Warrants

$2.50

$87.50

$1.50

$1.50

$1.50

Shares Underlying Convertible Note Warrant Description

The number of shares underlying each Convertible Note Warrant is the quotient of the face amount of the related Note divided by 87.5

Issuance Of Warrants To Placement Agents

28,464

Warrants Expired Date

0

Issuance Of Warrants To Lenders One

7,429

Proceeds from Issuance of Warrants

$650,000

Issuance Of Warrants To Lenders Two

58,000

Warrants Issued Accounted As Liability

7,429

Warrants Issued Accounted As Interest Expense

58,000

Common stock, shares issued

209,015,899

100,240,020

15,000,000

Warrants Strike Price Reduced Per Share

$1.75

Cashless Exercise Of Warrants

1,013,333

Shares Issued Exercise Of Warrants

1,515,306

11,000

4,000,000

11,000

2,881,680

29,525,879

Issuance Of Warrants To Consultant

700,000

6,000,000

2,881,680

Cash Exercise Of Warrants

$4,000,000

Warrants Exchanged For Preferred Shares

53,733,333

6,000,000

9,800,000

30,000,000

53,150,000

Income_Taxes_Details

Income Taxes (Details)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
U.S. federal statutory rate	-34.00%	-34.00%
State income tax, net of federal benefit	-6.00%	-6.00%
Change in valuation allowance	40.00%	40.00%
Income Tax provision (benefit)	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Deferred Tax Assets
Net operating losses	$7,120,000	$5,265,000
Derivative liability	2,146,800	1,355,000
Deferred Tax Assets, Gross, Total	9,266,800	6,620,000
Less: Valuation allowance	-7,120,000	-5,265,000
Deferred Tax Assets, Net of Valuation Allowance	2,146,800	1,355,000
Derivative liability	-2,146,800	-1,355,000
Total deferred tax liability	-2,146,800	-1,355,000
Net Deferred Tax Assets	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	-34.00%	-34.00%
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$17,800,000
Utilization Of Net Operating Losses Description	Utilization of the NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.

Capital_Deficiency_Details_Tex

Capital Deficiency (Details Textual) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

2 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Jun. 30, 2010

Jun. 30, 2008

Jun. 30, 2007

Jun. 30, 2013

Jun. 30, 2012

Apr. 30, 2010

Nov. 30, 2009

Jul. 31, 2007

Mar. 10, 2006

Jun. 30, 2005

Jun. 30, 2011

Jan. 31, 2011

Dec. 31, 2010

Dec. 31, 2010

Jun. 30, 2011

Nov. 03, 2010

Jun. 30, 2011

31-May-12

Jun. 30, 2010

Jun. 30, 2006

Feb. 28, 2013

Jan. 31, 2013

Sep. 30, 2012

Jun. 30, 2013

Apr. 30, 2013

Mar. 31, 2013

Jul. 31, 2012

Jun. 30, 2012

31-May-12

Apr. 30, 2012

Mar. 31, 2012

Feb. 29, 2012

Dec. 31, 2011

Oct. 31, 2011

Sep. 30, 2011

Jul. 31, 2011

Feb. 28, 2013

Jun. 30, 2013

31-May-13

Jun. 30, 2012

Jun. 30, 2007

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2011

Mar. 10, 2011

Mar. 09, 2011

Jan. 12, 2011

Dec. 28, 2008

31-May-13

Mar. 31, 2013

Jan. 31, 2013

Sep. 30, 2012

Aug. 31, 2010

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2010

Jun. 30, 2008

Jun. 30, 2006

Jun. 30, 2005

Aug. 31, 2012

Jun. 30, 2010

Jun. 30, 2010

Jun. 30, 2010

Mar. 31, 2012

Feb. 29, 2012

Mar. 14, 2011

Mar. 17, 2011

Jun. 30, 2013

Oct. 31, 2011

Convertible Promissory Notes 2007 [Member]

Convertible Promissory Notes April 2010 [Member]

Convertible Promissory Notes April 2010 [Member]

Convertible Promissory Notes April 2010 [Member]

Convertible Promissory Notes April 2010 [Member]

Convertible Promissory Notes April 2010 [Member]

Convertible Promissory Notes [Member]

Convertible Promissory Notes [Member]

November 2009 Notes [Member]

Series A Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

December 2010 Warrants [Member]

Director Warrants 2011 [Member]

Director Warrants 2011 [Member]

Convertible Promissory Notes April 2010 [Member]

Warrants And Consultant [Member]

Series B Convertible Preferred Stock [Member]

Stock Issued During Period Shares New Issues One To Founders

241,565

Stock Issued During Period Shares New Issues Two To Founders

183,505

Development Stage Entities, Equity Issuance, Per Share Amount

$0.00

Proceeds From Issuance Of Common Stock One

$12,078

Proceeds From Issuance Of Common Stock Two

9,175

Adjustments To Additional Paid In Capital Warrant Number

2,000

Warrants Expiration Date

20-Jun-08

Share Certificate Delivered Representing Common Stock Shares

2,000

Common Stock, Shares Authorized

2,000,000,000

2,000,000,000

40,000,000

13,000,000

2,000,000

Preferred Stock, Shares Authorized

15,000,000

25,000

25,000

25,000

25,000

1,000,000

1,000,000

1,000,000

Common Stock, Par Or Stated Value Per Share

$0.00

$0.00

$0.00

$0.00

Preferred Stock, Par Or Stated Value Per Share

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

Preferred Stock Shares Issued For Partial Settlement Of Claims

2,225

Preferred Stock Value Issued For Partial Settlement Of Claims

570,000

Preferred Stock Shares Exchanged For Common Stock Business Acquisition

2,577

Stock Issued During Period Shares To Convertible Promissory Note holders

6,595

Stock Issued During Period Shares Part Of Convertible Promissory Note Extension Agreement One

6,230

Convertible Promissory Note Maturity Extension Date One

30-Sep-07

Interest Expense, Capital Securities

622,354

Stock Issued During Period Shares Upon Conversion Of Convertible Promissory Note And Accrued Interest

365

Stock Issued During Period Value Upon Conversion Of Convertible Promissory Note And Accrued Interests

31,733

[1]

Convertible Promissory Note Maturity Extension Date Two

30-Jun-08

Convertible Promissory Note Maturity Extension Date Three

15-Dec-07

Stock Issued During Period Shares Exchanged Part Of Convertible Promissory Note Extension Agreement

600

Stock Issued During Period Shares Consulting Agreement

381,583

1,000

Common Stock Shares Retained By Acquirer

180,000

Stock Issued During Period Shares Conversion Of Preferred Stock And Interest

26,000,000

5,800,000

4,138,935

4,138,935

Stock Issued During Period Share To Purchasers Of Convertible Promissory Note

50,000

Stock Issued During Period Shares To Officer

50,000

Stock Issued During Period Shares To Replace Surrendered Shares

50,000

Stock Issued During Period Shares Sale Of Investment Units (in shares)

1,160,000

Stock Issued During Period Value Sale Of Investment Units

1,740,000

1,160

Stock Issued During Period, Shares, Issued for Services

9,500,000

5,000,000

1,750,000

2,500,000

500,000

13,750

1,327,583

Stock Issued During Period Shares As Part Of Settlement Of Claim Former Note holder

77,403

Stock Issued During Period Shares In Settlement Of Prior Debt

21,000

Stock Issued During Period Shares Cashless Exercise Of Warrants

46,000,000

29,525,879

3,443,877

32,570,671

1,765,240

1,765,240

1,928,571

Common Stock Issued For Repayment Of Debt

$262,338

Common Stock Shares Issued To Director

10,000

Common Stock Shares Issued To Consultants

70,000

Stock Issued During Period, Shares, Conversion of Convertible Securities

694,417

237,500

3,826,000

362,358

800,000

8,000,000

2,000,000

3,000,000

20,000,000

Convertible Preferred Stock, Shares Issued Upon Conversion

500,000

37,000,000

14,000,000

8,000,000

2,000,000

2,000,000

2,000,000

4,000,000

2,000,000

5,000,000

3,000,000

2,000,000

1,000,000

5,000,000

5,000,000

10

1,200,000

1,500,000

1,000,000

800,000

29,525,879

1,000,000

2,000,000

Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights

0.001

0.125

0.05

0.05

Shares Issued Exercise Of Warrants

1,515,306

3,714,286

2,881,680

Shares Issued To Vendor

545,000

Stock Issued During Period, Shares, New Issues

459,309

4,261,194

Stock Issued During Period Shares Conversion Of Senior Promissory Note And Interest

2,865,374

[1]

For the year ended June 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2009	Jun. 30, 2008	Jun. 30, 2007
Costs and Expenses, Related Party	$325,000
Related Party Transaction Payment To Related Party		100,000
Technology Services Costs		2,500
University Of South Florida Agreement [Member]
Related Party Transaction Principal Payment			209,148
Related Party Transaction Interest Payment			50,870
Related Party Transaction Installment Payment One			109,148
Related Party Transaction Installment Payment Two			100,000
Related Party Transaction Installment Monthly Payment			16,667
Related Party Transaction Installments Paid	184,151	50,435
Harlan Note [Member]
Debt Instrument, Face Amount		100,000
Debt Instrument, Interest Rate During Period		10.00%
Shares Issued As Collateral		4,300
Discharge Of Debt Instrument		104,244
Debt Instrument Issued To Shareholder		$104,244

StockBased_Compensation_Plans_1

Stock-Based Compensation Plans- (Details) (USD $)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2007
Options outstanding at June 30, 2012	213,243
Granted	0
Cancelled/Forfeited	0
Expired	0
Balance at the end of period	213,243	213,243
Options excercisable - Options	213,243
Options vested or expected to vest	213,243
Options outstanding - Weighted Average Exercise Price	$34.87
Granted - Weighted Average Exercise Price	$0		$37
Cancelled/Forfeited - Weighted Average Exercise Price	$0
Expired - Weighted Average Exercise Price	$0
Balance at the end of period - weighted Average Exercise Price	$34.87	$34.87
Options excercisable - Weighted Average Exercise Price	$34.87
Options vested or expected to vest - Weighted Average Exercise Price	$34.87
Options outstanding - Instrinisic value	$0
Cancelled/Forfeited - Instrinisic value	0
Balance at the end of period - Instrinisic value	0	0
Options excercisable - Instrinisic value	0
Options vested or expected to vest - Instrinisic value	$0
Options outstanding - Weighted Average Remaining Contractual Life	3 years 4 months 6 days	3 years 4 months 6 days
Granted - Weighted Average Remaining Contractual Life	0 years
Options excercisable - Weighted Average Remaining Contractual Life	3 years 4 months 6 days
Options vested or expected to vest - Weighted Average Remaining Contractual Life	3 years 4 months 6 days

StockBased_Compensation_Plans_2

Stock-Based Compensation Plans- (Details Textual) (USD $)	12 Months Ended					1 Months Ended	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2007	Jun. 30, 2007	Jun. 30, 2007	Jun. 30, 2011	Jun. 30, 2011	Jun. 30, 2009
				Chief Executive Officer [Member]	Chief Financial Officer [Member]	Consultant Warrants [Member]	Consultant Warrants [Member]	Consultant Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	26,757	26,757	240,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0			139,905	60,838
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$0		$37			$0.10
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Granted						10,000	2,000	500
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price							$0.83	$17.50
Share Based Compensation Arrangement By Share Based Payment Award Options Vested and Expected To Vest Exercisable Weighted Average Remaining Contractual Term 1						13-Jun-16	31-Aug-15	30-Mar-14
Share-based Compensation	$0	$256

Per_Share_Data_Details

Per Share Data (Details) (USD $)	12 Months Ended				98 Months Ended
	Jun. 30, 2013		Jun. 30, 2012		Jun. 30, 2013
Basic EPS
Net income (loss)	($9,755,510)		$1,896,990		($83,891,966)
Weighted average shares outstanding (in shares)	136,468,981		81,002,258
Basic income earnings per share (in dollars per share)	($0.07)		$0.02
Diluted EPS
Net income (loss)	-9,755,510		1,896,990		-83,891,966
Preferred stock dividends	2,592,550		2,278,171
Interest on convertible notes	290,005		192,293
Net income (loss) attributable to common stockholders, diluted	($6,872,955)		$4,367,454
Weighted average shares outstanding (in shares)	136,468,981		81,002,258
Diluted weighted average shares outstanding (in shares)	136,468,981	[1]	647,670,189	[1]
Convertible Debt [Member]
Diluted EPS
Weighted average number diluted shares outstanding adjustment	163,181,250		34,580,000
Series B Preferred Stock [Member]
Diluted EPS
Weighted average number diluted shares outstanding adjustment	4,593,090		4,593,090
Series C Preferred Stock [Member]
Diluted EPS
Weighted average number diluted shares outstanding adjustment	404,340,000		427,810,959
Warrant [Member]
Diluted EPS
Weighted average number diluted shares outstanding adjustment	104,552,263		99,683,882
Employee Stock Option [Member]
Diluted EPS
Weighted average number diluted shares outstanding adjustment	0		0
[1]	For the year ended June 30, 2013, all common stock equivalents have been determined to be anti-dilutive and have not been considered in the calculation of diluted weighted average shares outstanding on the statement of operations.

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Apr. 30, 2013

Mar. 31, 2013

Jul. 31, 2012

Jun. 30, 2012

31-May-12

Apr. 30, 2012

Mar. 31, 2012

Feb. 29, 2012

Dec. 31, 2011

Oct. 31, 2011

Sep. 30, 2011

Jul. 31, 2011

Jun. 30, 2013

Jun. 30, 2013

31-May-13

Jun. 30, 2013

Jun. 30, 2013

August 5, 2013 [Member]

July, 2013 [Member]

August, 2013 [Member]

September, 2013 [Member]

October 9, 2013 [Member]

October, 2013 [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Convertible Promissory Note and Warrants [Member]

Convertible Promissory Note and Warrants [Member]

Convertible Promissory Note and Warrants [Member]

Convertible Promissory Note and Warrants [Member]

August 7, 2013 [Member]

September 10, 2013 [Member]

September 16, 2013 [Member]

October 9, 2013 [Member]

Conversion of Stock, Amount Converted

$15,000,000

$675,000

$350,000

$825,000

$265,111

Convertible Preferred Stock Conversion Price Per Share

$0.05

$0.05

$0.05

$0.05

Convertible Preferred Stock, Total Shares Issued Upon Conversion

37,000,000

14,000,000

8,000,000

2,000,000

2,000,000

2,000,000

4,000,000

2,000,000

5,000,000

3,000,000

2,000,000

1,000,000

5,000,000

13,500,000

7,000,000

5,000,000

16,500,000

5,302,222

Face Amount Of Investment Units Sold

92,500

150,000

25,000

75,000

Proceeds From Investment Units Sold

$92,500

$150,000

$150,000

$75,000

Stock Issued During Period, Shares, Issued for Services

19,500,000